var title_f38_54_39776="Apply pin to foreskin1";
var content_f38_54_39776=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Applying safety pin to foreskin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_54_39776=[""].join("\n");
var outline_f38_54_39776=null;
var title_f38_54_39777="Clinical microbiology review: Genitourinary infections";
var content_f38_54_39777=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical microbiology review: Genitourinary infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/54/39777/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/54/39777/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/54/39777/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/54/39777/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/54/39777/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/54/39777/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/54/39777/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 32 year-old woman complains of dysuria and frequency; pyuria is seen in the urine sediment. What does the Gram stain show? Question: (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80918 \" href=\"mobipreview.htm?1/1/1055\">",
"     image 1",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef82014 \" href=\"mobipreview.htm?3/19/3391\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CASE 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 65 year-old woman complains of dysuria and frequency; pyuria is seen in the urine sediment. What does the Gram stain show? (",
"    <a class=\"graphic graphic_picture graphicRef59311 \" href=\"mobipreview.htm?41/0/41998\">",
"     picture 2",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef72089 \" href=\"mobipreview.htm?42/23/43390\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CASE 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;An 18 year-old woman complains of dysuria and frequency; pyuria is seen in the urine sediment. What does the Gram stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef50082 \" href=\"mobipreview.htm?40/53/41809\">",
"     picture 4",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef58728 \" href=\"mobipreview.htm?43/23/44401\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CASE 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;This specimen was obtained from a 42 year-old diabetic woman with a Foley catheter. What does the Gram stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef73608 \" href=\"mobipreview.htm?6/25/6559\">",
"     picture 6",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef53645 \" href=\"mobipreview.htm?7/37/7775\">",
"     picture 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CASE 5",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following swab was obtained from a 22 year-old male with a purulent urethral discharge. What does the Gram stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef64347 \" href=\"mobipreview.htm?10/31/10737\">",
"     picture 8",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef77330 \" href=\"mobipreview.htm?13/6/13409\">",
"     picture 9",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CASE 6",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following swab was obtained from a 25 year-old male with a mucopurulent urethral discharge. What does the Gram stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef51243 \" href=\"mobipreview.htm?14/35/14910\">",
"     picture 10",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef64040 \" href=\"mobipreview.htm?16/49/17182\">",
"     picture 11",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CASE 7",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 23 year-old woman has a vaginal discharge. What does the Gram stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef74814 \" href=\"mobipreview.htm?17/51/18238\">",
"     picture 12",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef54837 \" href=\"mobipreview.htm?19/13/19678\">",
"     picture 13",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CASE 8",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 26 year-old woman has a vaginal discharge. What does the Gram stain show? Question: (",
"    <a class=\"graphic graphic_picture graphicRef69669 \" href=\"mobipreview.htm?29/63/30704\">",
"     picture 14",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef78328 \" href=\"mobipreview.htm?31/47/32496\">",
"     picture 15",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CASE 9",
"    </span>",
"    &nbsp;&mdash;&nbsp;An 18 year-old man presents with a painless genital ulcer. What does this dark field examination show? Question: (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51039 \" href=\"mobipreview.htm?7/2/7213\">",
"     image 2",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef63806 \" href=\"mobipreview.htm?10/49/11037\">",
"     picture 16",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1271 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-3453397B85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_54_39777=[""].join("\n");
var outline_f38_54_39777=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CASE 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CASE 3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CASE 4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CASE 5",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CASE 6",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CASE 7",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CASE 8",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CASE 9",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1271\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1271|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?1/1/1055\" title=\"diagnostic image 1\">",
"      Gram stain urine 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?7/2/7213\" title=\"diagnostic image 2\">",
"      Penile ulcer dark field",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1271|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/19/3391\" title=\"picture 1\">",
"      Gram stain urine 1 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/0/41998\" title=\"picture 2\">",
"      Gram stain urine 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/23/43390\" title=\"picture 3\">",
"      Gram stain urine 2 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/53/41809\" title=\"picture 4\">",
"      Gram stain urine 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/23/44401\" title=\"picture 5\">",
"      Gram stain urine 3 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/25/6559\" title=\"picture 6\">",
"      Gram stain urine 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/37/7775\" title=\"picture 7\">",
"      Gram stain urine 4 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/31/10737\" title=\"picture 8\">",
"      Gram stain urethral discharge 5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/6/13409\" title=\"picture 9\">",
"      Gram stain urethral discharge 5 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/35/14910\" title=\"picture 10\">",
"      Gram stain urethral discharge 6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/49/17182\" title=\"picture 11\">",
"      Gram stain urethral discharge 6 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/51/18238\" title=\"picture 12\">",
"      Gram stain vagina 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/13/19678\" title=\"picture 13\">",
"      Gram stain of normal vaginal flora",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/63/30704\" title=\"picture 14\">",
"      Gram stain vagina 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/47/32496\" title=\"picture 15\">",
"      Gram stain bacterial vaginosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/49/11037\" title=\"picture 16\">",
"      Penile ulcer dark field answer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_54_39778="Patient information: Eosinophilic esophagitis (The Basics)";
var content_f38_54_39778=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86229\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/22/29024\">",
"         Upper digestive tract",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/39/37490\">",
"          Upper endoscopy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/2/24610\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/11/40114\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?7/13/7378\">",
"         Patient information: Dysphagia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/19/10546\">",
"         Patient information: Esophageal stricture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/27/35250\">",
"         Patient information: Food allergy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/43/30386\">",
"         Patient information: Inhalers (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/41/33426\">",
"         Patient information: Upper endoscopy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/30/38373\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/50/32547\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/47/29429\">",
"         Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Eosinophilic esophagitis (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H96540814\">",
"      <span class=\"h1\">",
"       What is eosinophilic esophagitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Eosinophilic esophagitis is a condition that affects the esophagus, the tube that carries food from the mouth to the stomach (",
"      <a class=\"graphic graphic_figure graphicRef55616 \" href=\"mobipreview.htm?28/22/29024\">",
"       figure 1",
"      </a>",
"      ). This condition is called &ldquo;EoE&rdquo; for short. In EoE, the esophagus has cells called &ldquo;eosinophils&rdquo; in it. Eosinophils are allergy cells that are not normally found in the esophagus.",
"     </p>",
"     <p>",
"      Doctors don&rsquo;t know for sure what causes EoE. But they think it might be caused by allergies, especially food allergies.",
"     </p>",
"     <p>",
"      EoE sometimes runs in families. It can happen in both children and adults.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H96540846\">",
"      <span class=\"h1\">",
"       What are the symptoms of eosinophilic esophagitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms can be different, depending on a person&rsquo;s age.",
"     </p>",
"     <p>",
"      Adults and teens usually have symptoms such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble swallowing &ndash; This is the most common symptom. People usually have trouble swallowing solid foods. Some people have pain with swallowing or feel like the food gets stuck in their throat or chest.",
"       </li>",
"       <li>",
"        Chest or upper belly pain",
"       </li>",
"       <li>",
"        Burning in the chest (heartburn) that doesn&rsquo;t get better after taking medicine to treat heartburn",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Children usually have symptoms such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeding problems, such as refusing to eat solid foods",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Belly pain",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H96540861\">",
"      <span class=\"h1\">",
"       Is there a test for eosinophilic esophagitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The test done most often to check for this condition is an upper endoscopy.",
"     </p>",
"     <p>",
"      During an upper endoscopy, a doctor (called a gastroenterologist) puts a thin tube with a camera and light on the end into your mouth and down into your esophagus (",
"      <a class=\"graphic graphic_figure graphicRef75392 \" href=\"mobipreview.htm?36/39/37490\">",
"       figure 2",
"      </a>",
"      ). He or she will look at the lining of the esophagus and take small samples of it. Another doctor will then look at the cells under a microscope to see if you have EoE.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H96540876\">",
"      <span class=\"h1\">",
"       How is eosinophilic esophagitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment usually involves diet changes and medicines:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Diet changes &ndash; Your doctor might have you avoid foods that could be causing your symptoms. There are 3 main ways to do this. You can:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Avoid the foods that most commonly cause EoE",
"       </li>",
"       <li>",
"        Avoid the foods you are allergic to &ndash; To figure out the foods you are allergic to, you might need to see an allergist (allergy doctor) and have tests.",
"       </li>",
"       <li>",
"        Go on a special liquid diet and avoid all solid foods",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      To make sure you get the nutrition you need, your doctor might recommend that you work with a dietitian (food expert). After your symptoms improve, you will be able to add foods back into your diet.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines &ndash; Doctors can use different medicines to treat EoE. One is called a &ldquo;proton pump inhibitor.&rdquo; This medicine is usually used to treat acid reflux, which is when acid that is normally in the stomach backs up into the esophagus. This medicine is used because people with EoE sometimes have acid reflux.",
"        <br/>",
"        <br/>",
"        Other medicines include steroids, which help reduce inflammation. (These are different from the steroids athletes take to build muscle.) Sometimes, steroids are breathed into the lungs, either from an inhaler or a device called a &ldquo;nebulizer.&rdquo; Other times, steroids come as a liquid or pill.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In some people, EoE leads to a condition called an esophageal stricture, which is a narrowing of the esophagus. The main treatment for an esophageal stricture is a procedure to widen the esophagus, called &ldquo;dilation.&rdquo; This procedure is done during endoscopy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H96540955\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/13/7378?source=see_link\">",
"       Patient information: Dysphagia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/41/33426?source=see_link\">",
"       Patient information: Upper endoscopy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/27/35250?source=see_link\">",
"       Patient information: Food allergy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/19/10546?source=see_link\">",
"       Patient information: Esophageal stricture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/11/40114?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/2/24610?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/43/30386?source=see_link\">",
"       Patient information: Inhalers (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=see_link\">",
"       Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/50/32547?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/30/38373?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/54/39778?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86229 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-C1F21EE0D5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_54_39778=[""].join("\n");
var outline_f38_54_39778=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96540814\">",
"      What is eosinophilic esophagitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96540846\">",
"      What are the symptoms of eosinophilic esophagitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96540861\">",
"      Is there a test for eosinophilic esophagitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96540876\">",
"      How is eosinophilic esophagitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96540955\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86229\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/22/29024\">",
"      Upper digestive tract",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/39/37490\">",
"       Upper endoscopy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/30/38373?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/2/24610?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/50/32547?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/11/40114?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/13/7378?source=related_link\">",
"      Patient information: Dysphagia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/19/10546?source=related_link\">",
"      Patient information: Esophageal stricture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/27/35250?source=related_link\">",
"      Patient information: Food allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=related_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/43/30386?source=related_link\">",
"      Patient information: Inhalers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_54_39779="Amcinonide: Patient drug information";
var content_f38_54_39779=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amcinonide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/51/12084?source=see_link\">",
"     see \"Amcinonide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amcort&reg;;",
"     </li>",
"     <li>",
"      Cyclocort&reg;;",
"     </li>",
"     <li>",
"      ratio-Amcinonide;",
"     </li>",
"     <li>",
"      Taro-Amcinonide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amcinonide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using on your face, groin, or underarm.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10779 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-C008A65255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_54_39779=[""].join("\n");
var outline_f38_54_39779=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132802\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014337\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014336\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014341\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014342\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014344\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014339\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014340\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014345\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014346\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/51/12084?source=related_link\">",
"      Amcinonide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_54_39780="Isoflurane: Patient drug information";
var content_f38_54_39780=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Isoflurane: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/63/17397?source=see_link\">",
"     see \"Isoflurane: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Forane&reg;;",
"     </li>",
"     <li>",
"      Terrell&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Forane&reg;;",
"     </li>",
"     <li>",
"      Isoflurane USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to put you to sleep for surgery.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to isoflurane or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703757",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you or a family member have had malignant hyperthermia after getting an anesthetic. Signs of this health problem include a very high fever, a fast heartbeat, muscle stiffness, and trouble breathing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697803",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may not be alert. Avoid driving and doing other tasks or actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698063",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Good mouth care may help. Ask the doctor for a drug to help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698330",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shivering.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698973",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696015",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a liquid for breathing into the lungs by a doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11498 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-5088ACF45B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_54_39780=[""].join("\n");
var outline_f38_54_39780=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184696\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855043\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020702\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020704\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020703\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020707\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020708\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020710\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020706\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020711\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020712\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/63/17397?source=related_link\">",
"      Isoflurane: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_54_39781="Pamidronate: Pediatric drug information";
var content_f38_54_39781=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pamidronate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"    see \"Pamidronate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/10/44196?source=see_link\">",
"    see \"Pamidronate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14289212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Review of Long-term Bisphosphonate Efficacy for Osteoporosis",
"     </span>",
"     <span class=\"collapsible-date\">",
"      May 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       In response to serious postmarketing adverse reactions, including atypical femur fractures, osteonecrosis of the jaw, and esophageal cancer, and a paucity of long-term efficacy data, the FDA conducted a systematic review of long-term bisphosphonate therapy for osteoporosis. To date, randomized controlled trials have shown that bisphosphonate therapy is effective in preventing fractures in trials of 3- to 4-years duration. Therefore, to examine long-term efficacy, three long-term extension trials (involving postmenopausal women) ranging in a duration of treatment from 6-10 years were used in the FDA&rsquo;s analysis. Based on the available long-term clinical trial data, the FDA was unable to identify subgroups of patients who are more likely to benefit from therapy beyond 3-5 years. Continuation of treatment should be based on individual assessment of risks, benefits, and preferences of patients and their physicians.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Until further data are available, the data suggests patients at low risk for fracture (eg, younger patients without a fracture history and bone mineral density [BMD] approaching normal) may be good candidates for discontinuation of therapy after 3-5 years. Patients at increased risk, such as older patients with a history of fracture and a BMD in the osteoporotic range, may benefit from continued therapy.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further investigation into the risks and benefits of long-term therapy, the usefulness of markers of bone turnover or BMD in determining duration or interruption of therapy, and surveillance or fracture risk after therapy discontinuation are needed.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to file://www.nejm.org/doi/pdf/10.1056/NEJMp1202619.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F205911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aredia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F205912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aredia&reg;;",
"     </li>",
"     <li>",
"      Pamidronate Disodium Omega;",
"     </li>",
"     <li>",
"      Pamidronate Disodium&reg;;",
"     </li>",
"     <li>",
"      PMS-Pamidronate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Hypercalcemia",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Bisphosphonate Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"      see \"Pamidronate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypercalcemia: I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Due to increased risk of nephrotoxicity, single doses should not exceed 90 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children (limited experience): 0.5-1 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Dosage based upon serum calcium measurement:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Serum calcium 12-13.5 mg/dL: 60-90 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Serum calcium &gt;13.5 mg/dL: 90 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Consider retreatment if the serum calcium becomes elevated again; allow a minimum of 7 days between each treatment to allow for a full response to the initial treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Osteogenesis imperfecta: Children (limited experience): 0.5-3 mg/kg/day for 3 days; may repeat in 4- to 6-month intervals; or as an alternative 10-30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     monthly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Osteopenia in nonambulatory children with cerebral palsy: Limited experience (Henderson, 2002); 1 mg/kg/day for 3 days; each dose not &lt;15 mg/day or &gt;30 mg/day; repeat at 3-month intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Osteolytic bone lesions of breast cancer or multiple myeloma: Adults: 90 mg/month; treatment should be withheld for renal deterioration (as defined per manufacturer: Patients with normal baseline creatinine: An increase of 0.5 mg/dL; patients with abnormal baseline creatinine: An increase of 1 mg/dL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Paget's disease: Adults: 30 mg for 3 consecutive days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Not recommended for use in patients with severe renal impairment; safety and efficacy have not been established in patients with serum creatinine &gt;5 mg/dL; limited studies have reported successful use in multiple myeloma patients with serum creatinine &ge;3 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      The manufacturer recommends the following guidelines:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of bone metastases: Use is not recommended in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal impairment in indications other than bone metastases:  Use clinical judgement to determine if benefit outweighs risks.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F205888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as disodium: 30 mg, 90 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aredia&reg;: 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as disodium: 3 mg/mL (10 mL); 6 mg/mL (10 mL); 9 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as disodium [preservative free]: 3 mg/mL (10 mL); 9 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F205873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstitute each vial with 10 mL SWI; dilute further in 250-1000 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, or NS (refer to manufacturer&rsquo;s information regarding dilution for specific treatments); do not mix with calcium-containing solutions (eg, LR); infuse over 2-24 hours; longer infusions (&gt;2 hours) may reduce the risk for renal toxicity, particularly in patients with pre-existing renal insufficiency",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F205960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with calcium-containing infusion solutions such as Ringer's injection.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1060819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstituted solution stable for 24 hours at room temperature or refrigerated; incompatible with calcium-containing I.V. fluids (ie, Ringer's solution)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic treatment of moderate to severe Paget's disease; hypercalcemia associated with malignancy; treatment of osteolytic bone lesions associated with multiple myeloma or metastatic breast cancer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Investigation use:",
"     </b>",
"     Inhibit bone resorption in severe osteogenesis imperfecta",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F205962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Aredia&reg; may be confused with Adriamycin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pamidronate may be confused with papaverine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F205958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Atrial fibrillation, atrial flutter, cardiac failure, edema, hypertension, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, fever, headache, pain, psychosis, seizure, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypocalcemia, hypokalemia, hypomagnesemia, hypophosphatemia, hypothyroidism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dyspepsia, gastrointestinal hemorrhage, nausea, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, granulocytopenia, leukopenia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Infusion site reaction (includes induration, pain, redness, and swelling)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, bone pain, myalgia, osteonecrosis of the jaw, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Serum creatinine increased, uremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pleural effusion, rales, rhinitis, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Moniliasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute renal failure, adult respiratory distress syndrome, allergic reaction, anaphylactic shock, angioedema, bone/joint/muscle pain (severe and occasionally incapacitating), bronchospasm, CHF, confusion, conjunctivitis, electrolyte/mineral abnormality, episcleritis, femoral fractures (atypical subtrochanteric, diaphyseal femoral), fluid overload, flu-like syndrome, focal segmental glomerulosclerosis (including collapsing variant), glomerulonephropathies, hallucinations (visual), hematuria, herpes virus reactivation, hyperkalemia, hypernatremia, hypotension, injection site phlebitis/thrombophlebitis, interstitial pneumonitis, iridocyclitis, iritis, joint and/or muscle pain (sometimes severe and/or incapacitating), left ventricular failure, lymphocytopenia, malaise, nephrotic syndrome, orbital inflammation, osteonecrosis (other than jaw), paresthesia, pruritus, rash, renal deterioration, renal failure, renal tubular disorders, scleritis, tetany, tubulointerstitial nephritis, uveitis, xanthopsia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pamidronate or any component; pregnancy; severe renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment; maintain adequate hydration and urinary output during treatment; use with caution with other potentially nephrotoxic drugs. Use has been associated with asymptomatic electrolyte abnormalities (including hypophosphatemia, hypokalemia, hypomagnesemia, and hypocalcemia).  Rare cases of symptomatic hypocalcemia, including tetany have been reported. Use with caution in patients with a history of thyroid surgery; patients may have relative hypoparathyroidism, predisposing them to pamidronate-related hypocalcemia.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1060815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Leukopenia has been observed with oral pamidronate; monitoring of white blood cell counts is suggested; vein irritation and thrombophlebitis may occur with I.V. infusions",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Osteonecrosis of the jaw has been reported in cancer patients receiving biphosphonates; many of these patients were also receiving corticosteroids and chemotherapy, the majority of cases were associated with dental procedures; a dental exam should be considered prior to treatment in cancer patients, especially those with risk factors (chemotherapy, corticosteroids, poor oral hygiene); while on treatment, avoid invasive dental procedures",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The Food and Drug Administration (FDA) is informing healthcare practitioners of the possible association between bisphosphonate use and the development of severe (possibly incapacitating) bone, muscle, and/or joint pain. The severe musculoskeletal pain may develop days, months, or years after initiating a bisphosphonate. This is a distinct event from the acute phase response (eg, fever, chills, bone pain, myalgia, arthralgia) that may occur following initial bisphosphonate administration which generally resolves within several days of continued use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Single pamidronate doses should not exceed 90 mg. Initial or single doses have been associated with renal deterioration, progressing to renal failure and dialysis. Glomerulosclerosis (focal segmental) with or without nephrotic syndrome, has also been reported, particularly in patients with multiple myeloma and breast cancer. Longer infusion times (&gt;2 hours) may reduce the risk for renal toxicity, especially in patients with pre-existing renal insufficiency.  Withhold pamidronate treatment (until renal function returns to baseline) in patients with evidence of renal deterioration. Monitor serum creatinine prior to each dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F205882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Bisphosphonate Derivatives may enhance the hypocalcemic effect of Phosphate Supplements.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: Bisphosphonate Derivatives may enhance the adverse/toxic effect of SUNItinib. Specifically, the risk of osteonecrosis of the jaw may be increased.  Management: Monitor for development of osteonecrosis of the jaw in patients receiving sunitinib and bisphosphonates.  Avoid invasive dental procedures if possible.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thalidomide: May enhance the nephrotoxic effect of Pamidronate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F205884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F205897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pamidronate has been shown to cross the placenta and cause adverse effects in animal reproduction studies. Bisphosphonates are expected to cross the human placenta. Bisphosphonates are incorporated into the bone matrix and gradually released over time. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy. Based on limited case reports, serum calcium levels in the newborn may be transiently altered if pamidronate is administered during pregnancy; shortened gestational age and low birth weight have also been noted, but significant fetal toxicity has not been observed. Women of childbearing potential should be advised to avoid becoming pregnant during therapy. Monitoring of calcium concentrations in the mother during pregnancy and in the neonate after birth are recommended if therapy is required (Stathopoulos, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1060821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor serum creatinine prior to each dose; monitor serum calcium, phosphate, potassium, and magnesium; patients with pre-existing anemia, leukopenia, or thrombocytopenia should have hemoglobin, hematocrit, and CBC with differential monitored closely, particularly in the first 2 weeks following treatment; in Paget's disease, monitor  serum alkaline phosphatase and urinary hydroxyproline excretion; dental exam and preventative dentistry for patients at risk for osteonecrosis",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pamidronate, a biphosphonate, lowers serum calcium concentrations by binding to bone and inhibiting osteoclast-mediated calcium resorption; this agent does not appear to produce any significant effect on renal tubular calcium handling",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1060827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of hypocalcemic action: 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 5-7 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Poorly from the GI tract; pharmacokinetic studies are lacking",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bone half-life: 300 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination: Adults with cancer: 28 &plusmn; 7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Biphasic: &sim;50% excreted unchanged in urine within 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Adults with cancer: Total: 107 &plusmn; 50 mL/minute; renal: 49 &plusmn; 28 mL/minute",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Falk MJ, Heeger S, Lynch KA, et al, &ldquo;Intravenous Bisphosphonate Therapy in Children With Osteogenesis Imperfecta,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2003, 111(3):573-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/54/39781/abstract-text/12612238/pubmed\" id=\"12612238\" target=\"_blank\">",
"        12612238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glorieux FH, Bishop NH, Plotkin H, et al, &ldquo;Cyclic Administration of Pamidronate in Children With Severe Osteogenesis Imperfecta,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 339(14):947-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/54/39781/abstract-text/9753709/pubmed\" id=\"9753709\" target=\"_blank\">",
"        9753709",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Henderson RC, Lark RK, Kecskemethy HH, et al, &ldquo;Bisphosphonates to Treat Osteopenia in Children With Quadriplegic Cerebral Palsy: A Randomized, Placebo-Controlled Clinical Trial,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2002, 141(5):644-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/54/39781/abstract-text/12410192/pubmed\" id=\"12410192\" target=\"_blank\">",
"        12410192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lteif AN and Zimmerman D, &ldquo;Bisphosphonates for Treatment of Childhood Hypercalcemia,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1998, 102(4 Pt 1):990-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/54/39781/abstract-text/9755274/pubmed\" id=\"9755274\" target=\"_blank\">",
"        9755274",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12673 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-79.122.249.114-3C057D9C1B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_54_39781=[""].join("\n");
var outline_f38_54_39781=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14289212\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205911\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205912\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060822\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060817\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205888\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205873\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060825\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205960\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060819\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060824\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205962\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205958\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060829\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060816\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060815\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299814\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205882\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205884\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205897\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060821\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060814\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060827\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060828\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12673\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12673|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=related_link\">",
"      Pamidronate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/10/44196?source=related_link\">",
"      Pamidronate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_54_39782="Albuterol (salbutamol): Pediatric drug information";
var content_f38_54_39782=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Albuterol (salbutamol): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"    see \"Albuterol (salbutamol): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/50/40741?source=see_link\">",
"    see \"Albuterol (salbutamol): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AccuNeb&reg;;",
"     </li>",
"     <li>",
"      ProAir&reg; HFA;",
"     </li>",
"     <li>",
"      Proventil&reg; HFA;",
"     </li>",
"     <li>",
"      Ventolin&reg; HFA;",
"     </li>",
"     <li>",
"      VoSpire ER&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F130977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Airomir&trade;;",
"     </li>",
"     <li>",
"      Apo-Salvent&reg;;",
"     </li>",
"     <li>",
"      Apo-Salvent&reg; AEM;",
"     </li>",
"     <li>",
"      Apo-Salvent&reg; CFC Free;",
"     </li>",
"     <li>",
"      Apo-Salvent&reg; Sterules;",
"     </li>",
"     <li>",
"      Dom-Salbutamol;",
"     </li>",
"     <li>",
"      Mylan-Salbutamol Respirator Solution;",
"     </li>",
"     <li>",
"      Mylan-Salbutamol Sterinebs P.F.;",
"     </li>",
"     <li>",
"      Novo-Salbutamol HFA;",
"     </li>",
"     <li>",
"      Nu-Salbutamol;",
"     </li>",
"     <li>",
"      PHL-Salbutamol;",
"     </li>",
"     <li>",
"      PMS-Salbutamol;",
"     </li>",
"     <li>",
"      ratio-Ipra-Sal;",
"     </li>",
"     <li>",
"      ratio-Salbutamol;",
"     </li>",
"     <li>",
"      Sandoz-Salbutamol;",
"     </li>",
"     <li>",
"      Teva-Salbutamol;",
"     </li>",
"     <li>",
"      Teva-Salbutamol Sterinebs P.F.;",
"     </li>",
"     <li>",
"      Ventolin&reg;;",
"     </li>",
"     <li>",
"      Ventolin&reg; Diskus;",
"     </li>",
"     <li>",
"      Ventolin&reg; HFA;",
"     </li>",
"     <li>",
"      Ventolin&reg; I.V. Infusion;",
"     </li>",
"     <li>",
"      Ventolin&reg; Nebules P.F.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenergic Agonist Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta",
"       <sub>",
"        2",
"       </sub>",
"       -Adrenergic Agonist",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Bronchodilator",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sympathomimetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11431419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nebulization: Usual reported dose: 1.25-2.5 mg/dose (Ballard, 2002). In a retrospective report, 16 VLBW neonates (mean GA: 26.1 &plusmn; 1.2 weeks; mean birthweight: 817 &plusmn; 211 g) received 1.25 mg/dose every 8 hours for &gt;2 weeks (Mhanna, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation, mechanically ventilated: MDI: 90 mcg/spray: 1-2 puffs administered into the ventilator circuit  was the most frequently reported dose in a survey of 68 neonatal intensive care units (Ballard, 2002); typically used every 6 hours (Fok, 1998); may consider more frequent use if clinically indicated",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"      see \"Albuterol (salbutamol): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute exacerbation, asthma",
"     </b>",
"     (NAEPP, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nebulization:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 0.15 mg/kg (minimum dose: 2.5 mg) every 20 minutes for 3 doses then 0.15-0.3 mg/kg (not to exceed 10 mg) every 1-4 hours as needed or 0.5 mg/kg/hour by continuous nebulization",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Continuous nebulized albuterol at 0.3 mg/kg/hour has also been used safely in the treatment of severe status asthmaticus in children; continuous nebulized doses of 3 mg/kg/hour &plusmn; 2.2 mg/kg/hour (Katz, 1993) in children whose mean age was 20.7 months resulted in no cardiotoxicity; the optimal dosage for continuous nebulization remains to be determined",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 2.5-5 mg every 20 minutes for 3 doses then 2.5-10 mg every 1-4 hours as needed or 10-15 mg/hour by continuous nebulization",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inhalation: MDI: 90 mcg/spray:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 4-8 puffs every 20 minutes for 3 doses then every 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 4-8 puffs every 20 minutes for up to 4 hours then every 1-4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Maintenance therapy, asthma (nonacute)",
"     </b>",
"     (NIH guidelines, 2007): Inhalation: MDI:",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended for long-term daily maintenance treatment; regular use exceeding 2 days/week for symptom control (not prevention of exercise-induced bronchospasm) indicates the need for additional long-term control therapy: 90 mcg/spray:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants, Children, Adolescents, and Adults: 2 inhalations every 4-6 hours as needed",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Albuterol Nebulization Dosage (Maintenance Therapy - Nonacute)",
"     </caption>",
"     <col align=\"left\" width=\"110\">",
"     </col>",
"     <col align=\"center\" width=\"97\">",
"     </col>",
"     <col align=\"center\" width=\"97\">",
"     </col>",
"     <col align=\"center\" width=\"97\">",
"     </col>",
"     <col align=\"center\" width=\"99\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5% Solution",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mL)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.083% Solution",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mL)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Frequency",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Infants and Children &lt;5 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.63-2.5 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.13-0.5 mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.76-3 mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Every 4-6 h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Children &ge;5 y and adults",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1.25-5 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.25-1 mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1.5-6 mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Every 4-8 h",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Manufacturer labeling:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;2 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10-15 kg: 1.25 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;15 kg: 2.5 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Not the preferred route for treatment of asthma; inhalation via nebulization or MDI is preferred (NIH guidelines, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release formulation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 2-6 years: 0.1-0.2 mg/kg/dose 3 times/day; maximum dose: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 6-12 years: 2 mg/dose 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &gt;12 years and Adults: 2-4 mg/dose 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sustained release formulation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children: 0.3-0.6 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided twice daily; maximum daily dose: 8 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &gt;12 years and Adults: 4 mg/dose twice daily; may increase to 8 mg/dose twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Exercise-induced bronchospasm:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inhalation: MDI: 90 mcg/spray:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children &lt;5 years: 1-2 inhalations 5 minutes before exercising",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;5 years and Adults: 2 inhalations 5 minutes before exercising",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nebulization: Children and Adults: See dosage table",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F130951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ProAir&reg; HFA: 90 mcg/inhalation (8.5 g) [chlorofluorocarbon free; 200 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Proventil&reg; HFA: 90 mcg/inhalation (6.7 g) [chlorofluorocarbon free; 200 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ventolin&reg; HFA: 90 mcg/inhalation (18 g) [chlorofluorocarbon free; 200 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ventolin&reg; HFA: 90 mcg/inhalation (8 g) [chlorofluorocarbon free; 60 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization: 0.083% [2.5 mg/3 mL] (30s, 60s); 0.5% [100 mg/20 mL] (1s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization [preservative free]: 0.021% [0.63 mg/3 mL] (25s); 0.042% [1.25 mg/3 mL] (25s, 30s); 0.083% [2.5 mg/3 mL] (25s, 30s, 60s); 0.5% [2.5 mg/0.5 mL] (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AccuNeb&reg;: 0.021% [0.63 mg/3 mL] (25s); 0.042% [1.25 mg/3 mL] (25s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral: 2 mg/5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2 mg, 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 4 mg, 8 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VoSpire ER&reg;: 4 mg, 8 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F130935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes aerosol",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation (metered-dose inhaler): Prime the inhaler (before first use or if it has not been used for more than 2 weeks) by releasing 4 test sprays into the air away from the face (3 test sprays for ProAir&reg; HFA); shake well before use; use spacer for children &lt;5 years of age and consider adding a face mask for infants and children &lt;4 years of age. HFA inhalers should be cleaned with warm water at least once per week; allow to air dry completely prior to use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nebulization: Using 0.5% solution, dilute dosage in 1-2 mL NS (0.083% solution and AccuNeb&trade; do not require further dilution); adjust nebulizer flow to deliver dosage over 5-15 minutes; avoid contact of the dropper tip (multidose bottle) with any surface, including the nebulizer reservoir and associated ventilator equipment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food; do not crush or chew extended release tablets",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F5167761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intravenous solution: Stable in water for injection, NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, and D",
"     <sub>",
"      5",
"     </sub>",
"     NS when mixed in PC bags or glass bottles. Avoid addition of other medications to infusion solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution for nebulization:",
"     <b>",
"      Compatible",
"     </b>",
"     with cromolyn sodium, budesonide inhalation suspension, ipratropium solution for nebulization",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1056297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liquid, tablets, MDIs, and oral inhalation solutions are stable at room temperature; discard Ventolin&reg; HFA MDI canister when counter reads \"000\" or 12 months after removal from moisture protective pouch, whichever occurs first; discard AccuNeb&trade; vial 1 week after removal from foil pouch or if solution is not colorless; oral inhalation solution compatible with cromolyn and ipratropium nebulizer solutions",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and relief of bronchospasm in patients with reversible airway obstruction due to asthma or COPD; prevention of exercise-induced bronchospasm",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F131035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Albuterol may be confused with Albutein&reg;, atenolol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Proventil&reg; may be confused with Bentyl&reg;, PriLOSEC&reg;, Prinivil&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Salbutamol may be confused with salmeterol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ventolin&reg; may be confused with phentolamine, Benylin&reg;, Vantin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F131033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Angina, atrial fibrillation, arrhythmias, chest discomfort, chest pain, extrasystoles, flushing, hyper-/hypotension, palpitation, supraventricular tachycardia, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: CNS stimulation, dizziness, drowsiness, headache, insomnia, irritability, lightheadedness, migraine, nervousness, nightmares, restlessness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hypokalemia, lactic acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, dry mouth, dyspepsia, gastroenteritis, nausea, unusual taste, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Micturition difficulty",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection: Pain, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps, musculoskeletal pain, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Otitis media, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma exacerbation, bronchospasm, cough, epistaxis, laryngitis,  oropharyngeal drying/irritation, oropharyngeal edema, pharyngitis, rhinitis, upper respiratory inflammation, viral respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, anaphylaxis, diaphoresis,  lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anxiety, glossitis, hoarseness, metabolic acidosis, myocardial ischemia, pulmonary edema, throat irritation, tongue ulceration",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to albuterol, any component, or adrenergic amine",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hyperthyroidism, seizure disorders, diabetes mellitus; cardiovascular disorders including coronary insufficiency, hypertension, or arrhythmia. CNS stimulation, hyperactivity, and insomnia occur more frequently in younger children than in adults.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhaled albuterol can produce paradoxical bronchospasm; discontinue therapy immediately if this occurs. Excessive or prolonged use can lead to tolerance; excessive use has also been associated with deaths, possibly due to cardiac arrest. Increasing use (&gt;2 days/week) for symptom relief (not prevention of exercise-induced asthma) generally indicates inadequate control of asthma and the need for initiating or intensifying anti-inflammatory treatment.  Regularly scheduled, daily, chronic use of short-acting beta agonists (eg, albuterol) is not recommended (NAEPP, 2007). Outbreaks of lower respiratory tract colonization and infection have been attributed to contaminated multidose albuterol bottles.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F130944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Blockers: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1056311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Caffeinated beverages may increase side effects of albuterol",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F130947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F130961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Albuterol crosses the placenta (Boulton, 1997). Congenital anomalies (cleft palate, limb defects) have rarely been reported following maternal use during pregnancy. Multiple medications were used in most cases, no specific pattern of defects has been reported, and no relationship to albuterol has been established. The amount of albuterol available systemically following inhalation is significantly less in comparison to oral doses.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Albuterol is the preferred short acting beta agonist when treatment for asthma is needed during pregnancy (NAEPP, 2005; NAEPP,  2007).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Albuterol may affect uterine contractility. Maternal pulmonary edema and other adverse events have been reported when albuterol was used for tocolysis. Albuterol is not approved for use as a tocolytic; use caution when needed to treat bronchospasm in pregnant women. Use of the injection (Canadian product; not available in the U.S.) is specifically contraindicated in women during the first or second trimester who may be at risk of threatened abortion.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium, oxygen saturation, heart rate, pulmonary function tests, respiratory rate, use of accessory muscles during respiration, suprasternal retractions; arterial or capillary blood gases (if patient's condition warrants)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relaxes bronchial smooth muscle by action on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors with little effect on heart rate",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1056307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nebulization/oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak bronchodilation: Within 0.5-2 hours nebulization",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak bronchodilatation: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release tablets: Duration: Up to 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: By the liver to an inactive sulfate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 2.7-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inhalation: 3.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 30% appears in urine as unchanged drug",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/50/40741?source=see_link\">",
"      see \"Albuterol (salbutamol): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not exceed recommended dosage; may cause dry mouth; rinse mouth with water following each inhalation to help with dry throat and mouth; if more than one inhalation is necessary, wait at least 1 full minute between inhalations; notify physician if palpitations, tachycardia, chest pain, muscle tremors, dizziness, headache, flushing, or if breathing difficulty persists; limit caffeinated beverages; to prevent medication build-up or blockage in the inhaler, the actuator, with the canister removed, should be washed and air-dried once weekly",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ballard J, Lugo RA, and Salyer JW, \"A Survey of Albuterol Administration Practices in Intubated Patients in the Neonatal Intensive Care Unit,\"",
"      <i>",
"       Respir Care",
"      </i>",
"      , 2002, 47(1):31-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/54/39782/abstract-text/11749685/pubmed\" id=\"11749685\" target=\"_blank\">",
"        11749685",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fok TF, Lam K, Ng PC, et al, \"Randomised Crossover Trial of Salbutamol Aerosol Delivered by Metered Dose Inhaler, Jet Nebuliser, and Ultrasonic Nebuliser in Chronic Lung Disease,\"",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 1998, 79(2):F100-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/54/39782/abstract-text/9828734/pubmed\" id=\"9828734\" target=\"_blank\">",
"        9828734",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Katz RW, Kelly HW, Crowley MR, et al, &ldquo;Safety of Continuous Nebulized Albuterol for Bronchospasm in Infants and Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1993, 92(5):666-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/54/39782/abstract-text/8414852/pubmed\" id=\"8414852\" target=\"_blank\">",
"        8414852",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mhanna MJ, Patel JS, Patel S, et al, \"The Effects of Racemic Albuterol Versus Levalbuterol in Very Low Birth Weight Infants,\"",
"      <i>",
"       Pediatr Pulmonol",
"      </i>",
"      , 2009, 44(8):778-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/54/39782/abstract-text/19598281/pubmed\" id=\"19598281\" target=\"_blank\">",
"        19598281",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics--2002,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2002, 110(5 Suppl):S141-219.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007; available at file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Callaghan C, Milner AD, and Swarbrick A, &ldquo;Nebulized Salbutamol Does Have a Protective Effect on Airways in Children Under One Year Old,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1988, 63(5):479-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/54/39782/abstract-text/3389861/pubmed\" id=\"3389861\" target=\"_blank\">",
"        3389861",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Papo MC, Frank J, and Thompson AE, &ldquo;A Prospective, Randomized Study of Continuous Versus Intermittent Nebulized Albuterol for Severe Status Asthmaticus in Children,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1993, 21(10):1479-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/54/39782/abstract-text/8403956/pubmed\" id=\"8403956\" target=\"_blank\">",
"        8403956",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rachelefsky GS and Siegel SC, &ldquo;Asthma in Infants and Children - Treatment of Childhood Asthma: Part II,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1985, 76(3):409-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/54/39782/abstract-text/2863296/pubmed\" id=\"2863296\" target=\"_blank\">",
"        2863296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuh S, Parkin P, Rajan A, et al, &ldquo;High- Versus Low-Dose, Frequently Administered, Nebulized Albuterol in Children With Severe, Acute Asthma,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1989, 83(4):513-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/54/39782/abstract-text/2927990 /pubmed\" id=\"2927990 \" target=\"_blank\">",
"        2927990",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuh S, Reider MJ, Canny G, et al, &ldquo;Nebulized Albuterol in Acute Childhood Asthma: Comparison of Two Doses,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(4):509-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/54/39782/abstract-text/2216613/pubmed\" id=\"2216613\" target=\"_blank\">",
"        2216613",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13290 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-190.102.30.19-0FE0C5A6F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_54_39782=[""].join("\n");
var outline_f38_54_39782=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130976\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130977\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056301\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11431419\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056294\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130951\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130935\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056305\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5167761\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056297\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056304\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131035\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131033\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056309\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056293\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056292\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298694\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130944\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056311\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130947\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130961\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056300\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056291\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056307\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056308\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056299\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13290\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13290|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=related_link\">",
"      Albuterol (salbutamol): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/50/40741?source=related_link\">",
"      Albuterol (salbutamol): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_54_39783="Dupuytren's contracture";
var content_f38_54_39783=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dupuytren's contracture",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/54/39783/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/54/39783/contributors\">",
"     Bruce C Anderson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/54/39783/contributors\">",
"     Rohit Aggarwal, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/54/39783/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/54/39783/contributors\">",
"     Zacharia Isaac, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/54/39783/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/54/39783/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/54/39783/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dupuytren&rsquo;s contracture is a relatively common disorder characterized by progressive fibrosis of the palmar fascia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/1\">",
"     1",
"    </a>",
"    ]. It is a benign, slowly progressive fibroproliferative disease of the palmar fascia. Initial tendon thickening is painless and often goes unnoticed and undiagnosed. Joint stiffness and a loss of full extension develop insidiously over decades.",
"   </p>",
"   <p>",
"    As the scarring process progresses, nodules form on the palmar fascia, and the finger gradually loses its flexibility, with contractures that draw one or more fingers into flexion at the metacarpophalangeal (MP) joint (",
"    <a class=\"graphic graphic_picture graphicRef70486 \" href=\"mobipreview.htm?35/58/36770\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/2\">",
"     2",
"    </a>",
"    ]. The term Dupuytren disease (DD) is also used for this disorder, as the fingers are not always held in a fixed flexion deformity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of Dupuytren&rsquo;s contracture is unknown; important factors include genetics, ethnicity, sex, and age and may include certain environmental factors and other diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/3\">",
"     3",
"    </a>",
"    ]. The disorder, which most affects those of northern European ancestry, appears to have a pronounced genetic predisposition; 68 percent of male relatives of affected patients develop the disease. In a study involving patients from the Netherlands, Germany, and the United Kingdom, six of nine genetic loci found associated with genetic susceptibility to Dupuytren&rsquo;s disease contained genes encoding proteins in the Wnt-signaling pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/4\">",
"     4",
"    </a>",
"    ]. Overstimulation of this pathway, which can regulate cellular proliferation, could potentially lead to fibroblast proliferation and nodule formation in this disorder through effects upon &beta;-catenin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathologically, Dupuytren&rsquo;s contracture is characterized by fibroblastic proliferation and disorderly collagen deposition with fascial thickening. Formation of a nodule or nodules occurs in the early proliferative stage of the disease and is the pathognomonic lesion of Dupuytren&rsquo;s contracture. Nodules form due to contraction of fibroblasts in the superficial palmar fascia and histologically are composed of fibroblasts and type III collagen. Smooth muscle fibroblasts and myofibroblasts are present in the nodules; increased concentrations of prostaglandins are also found within the nodules and may influence myofibroblast contractility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/6\">",
"     6",
"    </a>",
"    ]. The flexor tendons are not intrinsically involved, but invasion of the dermis occurs and results in characteristic puckering and tethering of the skin.",
"   </p>",
"   <p>",
"    The presence of CD3-positive lymphocytes and the expression of MHC class II proteins also suggest a possible role for a T-cell mediated autoimmune response in this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dupuytren's contracture has been observed in association with the following conditions and habits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/3,8-15\">",
"     3,8-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A literature review found that the incidence of Dupuytren&rsquo;s contracture is two to five times higher among workers exposed to repetitive handling tasks or vibration as compared with those not exposed such trauma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dupuytren&rsquo;s contracture occurs with increased frequency (16 to 42 percent) in adults with diabetes mellitus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22358?source=see_link\">",
"       \"Musculoskeletal complications in diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complex regional pain syndrome (reflex sympathetic dystrophy) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32344?source=see_link\">",
"       \"Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other localized fibroses such as nodular plantar fibromatosis, nodular fasciitis of popliteal fascia, and Peyronie&rsquo;s disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/12,13\">",
"       12,13",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17273?source=see_link\">",
"       \"Peyronie's disease: Diagnosis and medical management\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cigarette smoking and alcohol consumption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Palmar fasciitis, a distinct condition which can be mistaken for Dupuytren&rsquo;s contracture, is often associated with a malignancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An association of Dupuytren&rsquo;s contracture with epilepsy and with the use of anticonvulsants has been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/17-19\">",
"     17-19",
"    </a>",
"    ] but has not confirmed in all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/20\">",
"     20",
"    </a>",
"    ]. Dupuytren&rsquo;s disease has also been associated with increased mortality, particularly in patients who develop the disorder prior to age 60 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients present over the age of 50, and the prevalence increases with age. It occurs primarily in white males and is uncommon in African Americans and Asians. Approximately 80 percent of patients are men, and about 5 to 15 percent of males older than 50 years are affected. Symptom onset is earlier in men, and their disease may be more severe, progressing more rapidly. The relative frequency of patients who are women increases with advancing age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients typically complain of finger stiffness, thickening or a nodule in the palm, loss of motion of the affected finger or fingers, or all three. The patient often rubs the palm and fingers in an attempt to straighten them out when describing the condition. The lesion is usually painless; on rare occasions, concurrent tenosynovitis occurs and is painful. The ulnar side of both hands is involved in most patients, with the fourth and then fifth fingers usually affected earliest. The third finger is less often affected, and the index finger and thumb are typically spared.",
"   </p>",
"   <p>",
"    Two studies have indicated that plantar fibrosis, knuckle pads, and radial side involvement have a stronger influence on recurrence and extension of Dupuytren&rsquo;s disease than does bilateral hand involvement, little finger surgery, or early onset disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Dupuytren&rsquo;s contracture is clinical, based upon the history of painless stiffness of the fingers and upon the following findings on physical examination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The earliest sign of Dupuytren&rsquo;s contracture is a triangular &ldquo;puckering&rdquo; of the dermal tissue over the flexor tendon just proximal to the flexor crease of the finger. Passive extension of the affected fingers will demonstrate the puckering of the tendon as it courses over the MCP head.",
"     </li>",
"     <li>",
"      Discrete nodules may be visible and palpable along the course of the flexor tendons near distal palmar crease (",
"      <a class=\"graphic graphic_picture graphicRef70486 \" href=\"mobipreview.htm?35/58/36770\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef69444 \" href=\"mobipreview.htm?6/18/6433\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Mild tenderness may be present over the nodule; firm pressure exerted toward the underlying bone will cause pain that is most pronounced early in the course of the disease.",
"     </li>",
"     <li>",
"      The nodule typically progresses over a variable period of time to form a fibrous cord that extends from palm into the digits, causing a flexion contracture of the MCP joint. The nodules or cords may also originate in the digits, which can lead to proximal interphalangeal joint (PIP) contracture.",
"     </li>",
"     <li>",
"      Both the MCP and PIP joint contractures can result in permanent, irreversible flexion contractures of the affected joints (",
"      <a class=\"graphic graphic_picture graphicRef70486 \" href=\"mobipreview.htm?35/58/36770\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Signs of inflammation are absent in most cases; local tenderness, swelling, and pain with passive flexion and extension are absent unless a concurrent tenosynovitis is present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Soft tissue pads over the PIP joints on the extensor surface (knuckle pads) may be associated findings. Nodular lesions within the plantar fascia of the feet can develop concurrently.",
"   </p>",
"   <p>",
"    Plain x-rays of the hand are not necessary. Calcification of the tendons does not occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dupuytren&rsquo;s contracture should be distinguished from diabetic cheiroarthropathy (limited joint mobility), palmar fibromatosis (also referred to as palmar fasciitis), camptodactyly, traumatic scars, Volkmann&rsquo;s ischemic contracture, and intrinsic joint disease. Limited joint mobility in patients with diabetes involves all four fingers, whereas Dupuytren&rsquo;s contracture more commonly affects just the fourth and fifth digits, with the first and second fingers typically spared. In addition, the taut bands and nodules characteristic of Dupuytren&rsquo;s contracture are not commonly seen with cheiroarthropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12534?source=see_link\">",
"     \"Limited joint mobility in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Likewise, palmar fibromatosis causes progressive flexion contractures of all the fingers of both hands due to tethering of the flexor tendons to the palmar fascia and skin; although a rare disorder, it is an important consideration because the palmar fascial fibrosis is frequently associated with a malignant neoplasm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35496?source=see_link&amp;anchor=H12#H12\">",
"     \"Malignancy and rheumatic disorders\", section on 'Palmar fibromatosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treatment are to improve flexibility of the flexor tendons and to evaluate the need for surgery or other interventions. The therapy chosen depends upon the severity of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mild disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mild symptoms should be instructed to passively stretch the involved digits (hyperextending the digits), to avoid a tight grip on tools and other items (eg, by means of built-up handles using pipe insulation or cushion tape), and, when possible, to use a glove with padding across the palm during heavy grasping tasks.",
"   </p>",
"   <p>",
"    Patients can stretch the palms gently twice a day. Lanolin massage is helpful prior to stretching. Place the fingers on the edge of a table, palm down; then lift the palms upward gradually, keeping fingers flat to the table. Hold for 10 to 20 seconds, and perform five repetitions twice daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Persistent or progressive symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional glucocorticoid injection with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    hydrochloride may be helpful if local tenderness is bothersome (eg, the patient develops tenosynovitis) or if the palmar nodule is growing rapidly (",
"    <a class=\"graphic graphic_picture graphicRef66485 \" href=\"mobipreview.htm?31/42/32431\">",
"     picture 3",
"    </a>",
"    ). In one study, an average of 3.2 local injections of glucocorticoids led to significant disease regression, but complications included atrophy at the injection site or rupture of the flexor tendon. In some patients, there was no long-term impact on disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/26\">",
"     26",
"    </a>",
"    ]. Glucocorticoid injection is helpful in patients with more recent disease onset; longstanding scar tissue does not respond well to glucocorticoid injection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Flexion contractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard treatments for flexion contractures are surgical (open fasciectomy), as well as percutaneous or open fasciotomy or needle fasciotomy. Collagenase injection has also shown benefit in early and less severe disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the treatment of choice for advanced stages of disease, if function is impaired or if a contracture is progressing. At present, typical interventions are a transection of cords (fasciotomy) or an excision of diseased fascial bands (fasciectomy) with or without excision of the overlying skin. Surgery (limited or complete palmar fasciectomy) should be considered only when functional impairment is considerable. The initial results are generally good, but the recurrence rate is high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/27\">",
"     27",
"    </a>",
"    ]. Flexion deformities &gt;30 to 40 degrees at the metacarpophalangeal (MCP) or &gt;20 degrees at the proximal interphalangeal (PIP) joint have been suggested as indications for surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. PIP joint contractures are more likely to cause stiffness and are less likely to respond to surgery in advanced stages. The aims of surgery are to reverse digital contractures and to restore hand function. Surgery in younger patients has a much higher recurrence rate than in older patients. Unless gainful employment demands earlier intervention, patients should be encouraged to defer surgery until after age 70.",
"   </p>",
"   <p>",
"    The likelihood of recurrence after surgery may be related to the degree of cellularity of the lesion. A study of 10 patients found that signal characteristics on MRI predicted cellularity and, thus, may provide prognostic information regarding the likelihood of recurrence after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/29\">",
"     29",
"    </a>",
"    ]. A second operation can be performed in patients who have a recurrence after the first procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specific surgical technique used depends upon the individual characteristics of the patient and upon the preferences of the surgeon. More aggressive techniques such as radical fasciectomy or dermofasciectomy do not appear to offer an advantage over limited fasciectomies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Percutaneous needle aponeurotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous needle aponeurotomy, previously referred to as percutaneous needle fasciotomy, is sometimes utilized as a less invasive procedure to treat Dupuytren&rsquo;s contracture. Data from one retrospective series suggest that percutaneous needling of the palmar or digital fascia results in improved extension of the involved MCP or PIP joints, but contractures often recur. This was the conclusion of study of a series of 74 needle fasciotomies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/32\">",
"     32",
"    </a>",
"    ]. A much larger study of 1000 needle fasciotomies showed better results at the MCP joints compared with treatment at the PIP joints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/33\">",
"     33",
"    </a>",
"    ]. Substantial improvement (an average of 77 percent increase) was noted immediately after the needle fasciotomy, but a majority of contractures (65 percent) recurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/32\">",
"     32",
"    </a>",
"    ]. Among the reported complications of this technique are minor nerve damage, pseudoaneurysm formation, and flexor tendon injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited data suggest that surgical fasciotomy is superior to percutaneous needle aponeurotomy in terms of the total increase in extension, mainly at the MCP and PIP joints, but not in more subjective outcomes such as patient satisfaction and self-reported disability. When percutaneous needle aponeurotomy was directly compared with limited surgical fasciectomy in a six-week trial that randomly assigned 166 affected MCP rays, improvement in extension was significantly greater in those who received the open-surgical fasciectomy; the passive extension deficit measured in degrees decreased by 79 versus 63 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/35\">",
"     35",
"    </a>",
"    ]. Patient-reported satisfaction was similar in the two groups, and disability was less in those receiving the percutaneous needle aponeurotomy. In this study, there were no complications of needle fasciotomy. Limited fasciectomy was especially superior in the higher stages of disease (Tubiana stages III and IV). Percutaneous needle aponeurotomy may have some role in patients with milder disease (Tubiana stage I and II), because of quicker recovery and fewer complications.",
"   </p>",
"   <p>",
"    Additionally, in one study, patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    injection in combination with percutaneous aponeurotomy experienced a significantly greater degree of correction of flexion deformity at six months compared with those treated with percutaneous aponeurotomy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Collagenase injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Collagenase injection therapy is most effective for patients with less severe contractures (&lt;50 percent contracture) or with early stage disease. We use collagenase therapy rather than surgery as the initial intervention in patients with primary Dupuytren&rsquo;s contractures of the MCP and PIP joints that do not respond adequately to conservative management or to glucocorticoid injection. Its effectiveness in other areas with severe disease or in the treatment of recurrent disease is unknown. There have been no studies comparing collagenase therapy with traditional fasciectomies.",
"   </p>",
"   <p>",
"    The injection of clostridia histolyticum collagenase into the Dupuytren&rsquo;s lesion was beneficial in an open label study and in two randomized trials and may be an effective alternative to surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. The largest trial randomly assigned 308 patients with fixed flexion contractures of &ge;20 degrees at the MCP or PIP joints to receive up to three injections of collagenase clostridium histolyticum or placebo in the contracted collagen cord at 30-day intervals, with manipulation of the joints the day following injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/39\">",
"     39",
"    </a>",
"    ]. Cords injected with collagenase were significantly more likely to show a reduction in the contracture to 0 to 5 degrees of full extension 30 days after the last injection (64 versus 7 percent). The mean range of motion in the treated joints also improved significantly (from 44 to 81 degrees versus 45 to 50 degrees). Response rates were better in patients with less severe contractures.",
"   </p>",
"   <p>",
"    Patients treated with collagenase injection experienced significantly more treatment-related adverse events. However, these were mostly limited to local reactions. Patients who received collagenase injections developed peripheral edema (73 percent), contusions (51 percent), injection-site hemorrhage (37 percent), injection-site pain (32 percent), and upper extremity pain (31 percent). Few serious adverse events were noted among 204 collagenase-treated patients (two tendon ruptures and one case of complex regional pain syndrome). No systemic allergic reactions, nerve injuries, or changes in flexion or grip strength were seen. No recurrences were seen, but because follow-up was only for 30 days, no long term (six-month) recurrence information was determined.",
"   </p>",
"   <p>",
"    In a similar, but smaller, randomized trial, recurrence was observed in only 9 percent (5 of 62 joints) of successfully treated patients at the 24-month follow-up after the last injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic external beam radiation therapy can prevent progression and can provide symptomatic benefit in patients with mild to moderate flexion deformities. In one series, 198 affected hands (most less than 45 degrees, but up to 90 degrees of flexion deformity) in 129 patients were irradiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/40\">",
"     40",
"    </a>",
"    ]. Radiation was well-tolerated and was associated with a decrease in the mean number of cords, nodules, and skin changes. At 12 months, contractures regressed in over 50 percent and were stable in 37 percent, and only 2 percent required hand surgery for disease progression.",
"   </p>",
"   <p>",
"    In a long-term follow-up (mean of 13 years) of early stage Dupuytren&rsquo;s contracture treated with radiotherapy, more than 70 percent of patients remained stable or had regression of contractures in early stages (Tubiana stage",
"    <span class=\"nowrap\">",
"     N/I),",
"    </span>",
"    while disease progressed in most patients (&gt;60 percent) in stages I to II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/41\">",
"     41",
"    </a>",
"    ]. Most patients (66 percent) had long-term relief of local symptoms, such as burning sensations, itching, scratching, pressure, and tension. Radiotherapy did not increase the complication rate after surgery and was well-tolerated in most. There was no evidence for a second malignancy induced by radiotherapy.",
"   </p>",
"   <p>",
"    Other interventions, including continuous slow skeletal traction,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/22/33123?source=see_link\">",
"     dimethyl sulfoxide",
"    </a>",
"    , vitamin E,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    , physical therapy, ultrasound therapy, glucocorticoid injections, interferon, and splinting, have generally not been successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H439174064\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dupuytren&rsquo;s contracture runs a variable course. Some patients have little incapacity for many years, and regression occurs in approximately 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39783/abstract/43\">",
"     43",
"    </a>",
"    ]. In others, fibrous bands form and radiate distally so that, ultimately, the fingers are contracted by the taut bands and hand function is impaired. Without any therapy, progression is observed in about 50 percent of patients over six years of follow-up. All treatments are palliative; no therapy has been shown to stop the scarring process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/41/31377?source=see_link\">",
"       \"Patient information: Dupuytren&rsquo;s contracture (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/11/7347?source=see_link\">",
"       \"Patient information: Hand pain (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H336491935\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dupuytren&rsquo;s contracture is a relatively common, benign, slowly progressive fibroproliferative disease of the palmar fascia. Initial tendon thickening is painless and often goes unnoticed and undiagnosed. As the scarring process progresses, nodules form on the palmar fascia, and the finger gradually loses its flexibility, with contractures that draw one or more fingers into flexion at the metacarpophalangeal (MP) joint. Pathologically, Dupuytren&rsquo;s contracture is characterized by fibroblastic proliferation and disorderly collagen deposition with fascial thickening. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cause of Dupuytren&rsquo;s contracture is unknown. It exhibits a pronounced genetic predisposition and is more common in northern Europeans; genes encoding proteins in the Wnt-signaling pathway appear involved. Associated conditions include repetitive hand use and vibratory trauma; diabetes mellitus, complex regional pain syndrome; the presence of other localized fibrosing conditions; and cigarette smoking and alcohol consumption. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients present over the age of 50. The incidence increases with age, and about 5 to 15 percent of males older than 50 years are affected. The relative frequency of female patients increases with advancing age. Patients typically complain of finger stiffness, thickening or a nodule in the palm, loss of motion of the affected finger or fingers, or all three. The lesion is usually painless, although mild tenderness may be present over the nodules. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of Dupuytren&rsquo;s contracture is clinical, based upon the history of painless stiffness of the fingers and upon the presence of characteristic findings on physical examination. Dupuytren&rsquo;s contracture should be distinguished from diabetic cheiroarthropathy (limited joint mobility), palmar fibromatosis (also referred to as palmar fasciitis), camptodactyly, traumatic scars, Volkmann&rsquo;s ischemic contracture, and intrinsic joint disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of treatment are to improve flexibility of the flexor tendons and to evaluate the need for surgery or other interventions. The therapy chosen depends upon the severity of disease. Patients with mild symptoms should be instructed to passively stretch the involved digits, to avoid a tight grip on tools and other items, and, when possible, to use a glove with padding across the palm during heavy grasping tasks. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Mild disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intralesional glucocorticoid injection with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      acetonide and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      hydrochloride may be helpful if local tenderness is bothersome (eg, the patient develops tenosynovitis) or if the palmar nodule is growing rapidly. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Persistent or progressive symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The standard treatments for moderate to severe flexion contractures are surgical (open fasciectomy), as well as percutaneous or open fasciotomy or needle aponeurotomy. Collagenase injection with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      injection has also shown benefit in early and less severe disease. Regardless of the treatment modality, all patients receive posttreatment range of motion stretching exercises, with or without night splinting. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Flexion contractures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Percutaneous needle aponeurotomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Collagenase injection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dupuytren&rsquo;s contracture runs a variable course. Some patients have little incapacity for many years, and regression occurs in approximately 10 percent. In others, fibrous bands form and radiate distally so that, ultimately, the fingers are contracted by the taut bands and hand function is impaired. Without any therapy, progression is observed in about 50 percent of patients over six years of follow-up. (See",
"      <a class=\"local\" href=\"#H439174064\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20818044\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate, Inc. would like to acknowledge Robert P Sheon, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/1\">",
"      Gudmundsson KG, J&oacute;nsson T, Arngr&iacute;msson R. Guillaume Dupuytren and finger contractures. Lancet 2003; 362:165.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson BC. Office Orthopedics for Primary Care: Diagnosis and Treatment, 2nd, WB Saunders, Philadelphia 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/3\">",
"      Shih B, Bayat A. Scientific understanding and clinical management of Dupuytren disease. Nat Rev Rheumatol 2010; 6:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/4\">",
"      Dolmans GH, Werker PM, Hennies HC, et al. Wnt signaling and Dupuytren's disease. N Engl J Med 2011; 365:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/5\">",
"      Bowley E, O'Gorman DB, Gan BS. Beta-catenin signaling in fibroproliferative disease. J Surg Res 2007; 138:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/6\">",
"      Badalamente MA, Hurst LC, Sampson SP. Prostaglandins influence myofibroblast contractility in Dupuytren's disease. J Hand Surg Am 1988; 13:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/7\">",
"      Baird KS, Alwan WH, Crossan JF, Wojciak B. T-cell-mediated response in Dupuytren's disease. Lancet 1993; 341:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/8\">",
"      Liss GM, Stock SR. Can Dupuytren's contracture be work-related?: review of the evidence. Am J Ind Med 1996; 29:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/9\">",
"      Matsen FA 3rd, Kirby RM. Office evaluation and management of shoulder pain. Orthop Clin North Am 1982; 13:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/10\">",
"      Bridgman JF. Periarthritis of the shoulder and diabetes mellitus. Ann Rheum Dis 1972; 31:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/11\">",
"      Lynch M, Jayson MIV. Fasciitis and fibrosis. Clin Rheum Dis 1979; 5:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/12\">",
"      Wooldridge WE. Four related fibrosing diseases. When you find one, look for another. Postgrad Med 1988; 84:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/13\">",
"      Wheeler ES, Meals RA. Dupuytren's diathesis: a broad-spectrum disease. Plast Reconstr Surg 1981; 68:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/14\">",
"      Burge P, Hoy G, Regan P, Milne R. Smoking, alcohol and the risk of Dupuytren's contracture. J Bone Joint Surg Br 1997; 79:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/15\">",
"      Frey M. Risks and prevention of Dupuytren's contracture. Lancet 1997; 350:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/16\">",
"      Leslie BM. Palmar fasciitis and polyarthritis associated with a malignant neoplasm: a paraneoplastic syndrome. Orthopedics 1992; 15:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/17\">",
"      Critchley EM, Vakil SD, Hayward HW, Owen VM. Dupuytren's disease in epilepsy: result of prolonged administration of anticonvulsants. J Neurol Neurosurg Psychiatry 1976; 39:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/18\">",
"      Arafa M, Noble J, Royle SG, et al. Dupuytren's and epilepsy revisited. J Hand Surg Br 1992; 17:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/19\">",
"      Tripoli M, Cordova A, Moschella F. Dupuytren's contracture as result of prolonged administration of phenobarbital. Eur Rev Med Pharmacol Sci 2011; 15:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/20\">",
"      Geoghegan JM, Forbes J, Clark DI, et al. Dupuytren's disease risk factors. J Hand Surg Br 2004; 29:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/21\">",
"      Mikkelsen OA, H&oslash;yeraal HM, Sandvik L. Increased mortality in Dupuytren's disease. J Hand Surg Br 1999; 24:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/22\">",
"      Ross DC. Epidemiology of Dupuytren's disease. Hand Clin 1999; 15:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/23\">",
"      Anthony SG, Lozano-Calderon SA, Simmons BP, Jupiter JB. Gender ratio of Dupuytren's disease in the modern U.S. population. Hand (N Y) 2008; 3:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/24\">",
"      Abe Y, Rokkaku T, Ofuchi S, et al. An objective method to evaluate the risk of recurrence and extension of Dupuytren's disease. J Hand Surg Br 2004; 29:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/25\">",
"      Abe Y, Rokkaku T, Ofuchi S, et al. Dupuytren's disease on the radial aspect of the hand: report on 135 hands in Japanese patients. J Hand Surg Br 2004; 29:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/26\">",
"      Ketchum LD, Donahue TK. The injection of nodules of Dupuytren's disease with triamcinolone acetonide. J Hand Surg Am 2000; 25:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/27\">",
"      Townley WA, Baker R, Sheppard N, Grobbelaar AO. Dupuytren's contracture unfolded. BMJ 2006; 332:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/28\">",
"      Trojian TH, Chu SM. Dupuytren's disease: diagnosis and treatment. Am Fam Physician 2007; 76:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/29\">",
"      Yacoe ME, Bergman AG, Ladd AL, Hellman BH. Dupuytren's contracture: MR imaging findings and correlation between MR signal intensity and cellularity of lesions. AJR Am J Roentgenol 1993; 160:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/30\">",
"      Roush TF, Stern PJ. Results following surgery for recurrent Dupuytren's disease. J Hand Surg Am 2000; 25:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/31\">",
"      Ullah AS, Dias JJ, Bhowal B. Does a 'firebreak' full-thickness skin graft prevent recurrence after surgery for Dupuytren's contracture?: a prospective, randomised trial. J Bone Joint Surg Br 2009; 91:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/32\">",
"      van Rijssen AL, Werker PM. Percutaneous needle fasciotomy in dupuytren's disease. J Hand Surg Br 2006; 31:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/33\">",
"      McMillan C, Binhammer P. Steroid injection and needle aponeurotomy for Dupuytren contracture: a randomized, controlled study. J Hand Surg Am 2012; 37:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/34\">",
"      Symes T, Stothard J. Two significant complications following percutaneous needle fasciotomy in a patient on anticoagulants. J Hand Surg Br 2006; 31:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/35\">",
"      van Rijssen AL, Gerbrandy FS, Ter Linden H, et al. A comparison of the direct outcomes of percutaneous needle fasciotomy and limited fasciectomy for Dupuytren's disease: a 6-week follow-up study. J Hand Surg Am 2006; 31:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/36\">",
"      Pess GM, Pess RM, Pess RA. Results of needle aponeurotomy for Dupuytren contracture in over 1,000 fingers. J Hand Surg Am 2012; 37:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/37\">",
"      Badalamente MA, Hurst LC. Enzyme injection as nonsurgical treatment of Dupuytren's disease. J Hand Surg Am 2000; 25:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/38\">",
"      Badalamente MA, Hurst LC. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren's contracture. J Hand Surg Am 2007; 32:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/39\">",
"      Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med 2009; 361:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/40\">",
"      Seegenschmiedt MH, Olschewski T, Guntrum F. Radiotherapy optimization in early-stage Dupuytren's contracture: first results of a randomized clinical study. Int J Radiat Oncol Biol Phys 2001; 49:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/41\">",
"      Betz N, Ott OJ, Adamietz B, et al. Radiotherapy in early-stage Dupuytren's contracture. Long-term results after 13 years. Strahlenther Onkol 2010; 186:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/42\">",
"      Hurst LC, Badalamente MA. Nonoperative treatment of Dupuytren's disease. Hand Clin 1999; 15:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39783/abstract/43\">",
"      Gudmundsson KG, Arngrimsson R, J&oacute;nsson T. Eighteen years follow-up study of the clinical manifestations and progression of Dupuytren's disease. Scand J Rheumatol 2001; 30:31.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7753 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_54_39783=[""].join("\n");
var outline_f38_54_39783=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H336491935\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mild disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Persistent or progressive symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Flexion contractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Percutaneous needle aponeurotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Collagenase injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H439174064\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H336491935\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20818044\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7753\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7753|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/58/36770\" title=\"picture 1\">",
"      Dupuytrens contracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/18/6433\" title=\"picture 2\">",
"      Palpation of palmar fascia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/42/32431\" title=\"picture 3\">",
"      Injection Dupuytrens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32344?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12534?source=related_link\">",
"      Limited joint mobility in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35496?source=related_link\">",
"      Malignancy and rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22358?source=related_link\">",
"      Musculoskeletal complications in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/41/31377?source=related_link\">",
"      Patient information: Dupuytren&rsquo;s contracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/11/7347?source=related_link\">",
"      Patient information: Hand pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17273?source=related_link\">",
"      Peyronie's disease: Diagnosis and medical management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_54_39784="Left bundle branch block";
var content_f38_54_39784=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Left bundle branch block",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/54/39784/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/54/39784/contributors\">",
"     William H Sauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/54/39784/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/54/39784/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/54/39784/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/54/39784/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/54/39784/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left bundle branch block (LBBB), a pattern seen on the surface electrocardiogram (ECG), results when normal electrical activity in the His-Purkinje system is interrupted (",
"    <a class=\"graphic graphic_figure graphicRef63340 \" href=\"mobipreview.htm?42/52/43841\">",
"     figure 1",
"    </a>",
"    ). The normal sequence of activation is altered dramatically in LBBB, with a resultant characteristic appearance on the ECG (",
"    <a class=\"graphic graphic_waveform graphicRef61594 \" href=\"mobipreview.htm?42/28/43466\">",
"     waveform 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    LBBB most often occurs in patients with underlying heart disease and may be associated with progressive conducting system disease. However, LBBB can also be seen in asymptomatic patients with a structurally normal heart. The presence of LBBB complicates the diagnosis of myocardial",
"    <span class=\"nowrap\">",
"     ischemia/infarction",
"    </span>",
"    and interferes with the interpretation of exercise testing. In patients with significant LV dysfunction, LBBB results in left ventricular dyssynchrony and may contribute to heart failure.",
"   </p>",
"   <p>",
"    The anatomy, clinical manifestations, differential diagnosis, prognostic implications, and treatment of LBBB will be reviewed here. Additional details regarding the ECG manifestations of LBBB are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22038?source=see_link&amp;anchor=H6#H6\">",
"     \"ECG tutorial: Intraventricular block\", section on 'Left bundle branch block'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H618484\">",
"    <span class=\"h1\">",
"     ANATOMY AND ELECTROPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175255\">",
"    <span class=\"h2\">",
"     Anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bundle of His divides at the juncture of the fibrous and muscular boundaries of the interventricular septum into the right and left bundle branches. The main left bundle branch penetrates the membranous portion of the interventricular septum under the aortic ring and then divides into several fairly discrete branches. The components of the left bundle branch are (",
"    <a class=\"graphic graphic_figure graphicRef63340 \" href=\"mobipreview.htm?42/52/43841\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pre-divisional segment.",
"     </li>",
"     <li>",
"      An anterior fascicle that crosses the left ventricular outflow tract and terminates in the Purkinje system of the anterolateral wall of the left ventricle.",
"     </li>",
"     <li>",
"      A posterior fascicle that fans out extensively inferiorly and posteriorly into Purkinje fibers.",
"     </li>",
"     <li>",
"      In some hearts, a median fascicle to the interventricular septum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175262\">",
"    <span class=\"h2\">",
"     Blood supply",
"    </span>",
"    &nbsp;&mdash;&nbsp;The left anterior descending artery provides the primary blood supply for the left bundle branch, particularly for the initial portion (",
"    <a class=\"graphic graphic_figure graphicRef70956 \" href=\"mobipreview.htm?21/44/22213\">",
"     figure 2",
"    </a>",
"    ). As is true for the right bundle branch, there may be some collateral flow from the right and circumflex coronary systems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175319\">",
"    <span class=\"h2\">",
"     Electrophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main left bundle and its fascicles consist of Purkinje fibers that transmit impulses at a rate of 1 to 3",
"    <span class=\"nowrap\">",
"     m/sec",
"    </span>",
"    resulting in virtual simultaneous depolarization of the terminal His Purkinje system and the adjacent ventricular myocardium. Pathological studies in LBBB have suggested that the block may be proximal (particularly in diffuse myocardial disease), distal, or a combination of both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electrophysiologic studies have revealed multiple and complicated patterns of myocardial activation, the heterogeneity of which depends upon the function or dysfunction of the distal specialized conduction system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/7\">",
"     7",
"    </a>",
"    ]. Changes in myocardial activation only affect the left ventricle in LBBB; thus, changes in the morphologic features of local electrograms can be recorded in the left, but not the right, ventricle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An LV activation pattern study in patients with chronic heart failure and LBBB on ECG was studied in seven patients with an LV ejection fraction of less than 35 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/9\">",
"     9",
"    </a>",
"    ]. Three patients had preserved activation of the left bundle despite LBBB on the ECG. Four had conduction block. The remainder had homogeneous depolarization propagation within the LV. These findings suggest that there are variable patterns of LV endocardial activation, which may be important in cardiac resynchronization therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/36/10823?source=see_link\">",
"     \"Rationale for and mechanisms of benefit of cardiac resynchronization therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of LBBB increases with age, occurring in less than 1 percent of the general population, with estimates ranging from 0.2 to 1.1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. LBBB occurs infrequently in young healthy subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. As an example, a study of 237,000 airmen under age 30 found only 125 cases of LBBB, representing a prevalence of 0.05 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/17\">",
"     17",
"    </a>",
"    ]. Ninety percent of these subjects had no apparent structural heart disease, and an isolated LBBB in young men was generally benign.",
"   </p>",
"   <p>",
"    The increase in LBBB prevalence with age was illustrated in a prospective study of 855 Swedish men in the general population who were 50 years of age and followed for 30 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/15\">",
"     15",
"    </a>",
"    ]. The prevalence of LBBB was 0.4 percent at age 50, 2.3 percent by age 75, and 5.7 percent by age 80. In this otherwise healthy population, there was no significant association with risk factors for or the presence of ischemic heart disease, myocardial infarction or cardiovascular deaths, suggesting that LBBB is more commonly a marker of a slowly progressive degenerative disease of the conduction system. Among 66,450 participants in the Women's Health Initiative trial, 714 had LBBB at study entry, representing a prevalence of 1.1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the Swedish study, other studies have suggested an association between the new onset of LBBB and underlying advanced",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    advancing heart disease, particularly in older adults. This is illustrated in the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 5209 persons from the Framingham Heart Study followed for 18 years, 55 subjects developed LBBB at a mean age of 62 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/19\">",
"       19",
"      </a>",
"      ]. Patients who developed LBBB had significantly higher rates of antecedent hypertension, cardiomegaly, and coronary heart disease. Coincident with or subsequent to the onset of the LBBB, 48 percent developed clinically apparent coronary disease or heart failure for the first time. Over the period of follow-up, only 11 percent of those who developed LBBB remained free of cardiovascular disease compared to 50 percent in an age-matched control group without LBBB.",
"     </li>",
"     <li>",
"      Among 110,000 Irish subjects who underwent screening for cardiovascular disease, 112 were found to have LBBB [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/20\">",
"       20",
"      </a>",
"      ]. At a mean follow-up of 9.5 years, patients with LBBB demonstrated a significantly increased prevalence of cardiovascular disease (21 versus 11 percent in patients without LBBB).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of underlying cardiovascular disease is lower in younger subjects with LBBB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. However, because of the association of LBBB with the subsequent development of cardiovascular disease, even in otherwise asymptomatic patients, careful evaluation and follow-up are indicated. When LBBB is present, patients should be evaluated for hypertension, coronary disease, and other disorders that have been associated with LBBB (eg, myocarditis, valvular heart disease, cardiomyopathies) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/6,21,22\">",
"     6,21,22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175977\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to the right bundle branch, conduction in the left bundle branch can be compromised by both structural and functional factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175985\">",
"    <span class=\"h2\">",
"     Structural heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excepting cases of acute anterior MI, LBBB is not generally the result of a single clinical entity but rather results from slowly progressive degenerative disease involving the conduction system. As such, numerous chronic conditions which contribute to myocardial fibrosis (eg, hypertension, coronary artery disease, cardiomyopathies) can contribute to the development of LBBB.",
"   </p>",
"   <p>",
"    LBBB may result following an acute myocardial insult such as myocardial ischemia, myocardial infarction, or myocarditis and in such circumstances is usually associated with a worse prognosis. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Prognosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4282?source=see_link\">",
"     \"Conduction abnormalities after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/16/26889?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\", section on 'Electrocardiogram'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176001\">",
"    <span class=\"h2\">",
"     Functional LBBB",
"    </span>",
"    &nbsp;&mdash;&nbsp;LBBB may be functional, as a result of a long preceding R-R interval following by a short cycle (\"rate-related bundle branch block\"). Functional LBBB may be sustained if, after the initial aberration, the impulse traveling down the right bundle branch reenters the left bundle branch rendering it again refractory, and this pattern repeats for several cycles.",
"   </p>",
"   <p>",
"    Ventricular tachycardia may mimic LBBB, as in repetitive monomorphic ventricular tachycardia originating from the right ventricular outflow tract or in bundle branch reentrant ventricular tachycardia (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26858?source=see_link\">",
"     \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41637?source=see_link\">",
"     \"Bundle branch reentrant ventricular tachycardia\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Hyperkalemia can depress conduction in the His-Purkinje system and rarely causes LBBB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35558?source=see_link&amp;anchor=H11#H11\">",
"     \"ECG tutorial: Miscellaneous diagnoses\", section on 'Hyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H618500\">",
"    <span class=\"h1\">",
"     ELECTROCARDIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The abnormalities in conduction and activation of the myocardium in persons with LBBB result in two major changes: loss of normal early septal forces, and the development of large and prolonged QRS complexes in the leftward leads (I, avL, and V6).",
"   </p>",
"   <p>",
"    A task force from the American Heart Association, the American College of Cardiology, and the Heart Rhythm Society has defined the electrocardiographic features of LBBB. These criteria incorporate the activation forces described above and include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      QRS duration greater than or equal to 120 ms in adults, greater than 100 ms in children 4 to 16 years of age, and greater than 90 ms in children less than four years of age.",
"     </li>",
"     <li>",
"      Broad notched or slurred R wave in leads I, aVL, V5, and V6 and an occasional RS pattern in V5 and V6 attributed to displaced transition of QRS complex.",
"     </li>",
"     <li>",
"      Absent q waves in leads I, V5, and V6, but in the lead aVL, a narrow q wave may be present in the absence of myocardial pathology.",
"     </li>",
"     <li>",
"      R peak time greater than 60 ms in leads V5 and V6 but normal in leads V1, V2, and V3, when small initial r waves can be discerned in the above leads.",
"     </li>",
"     <li>",
"      ST and T waves usually opposite in direction to QRS complex.",
"     </li>",
"     <li>",
"      Sometimes positive T wave in leads with upright QRS complexes may be normal (\"positive QRS-T\" concordance).",
"     </li>",
"     <li>",
"      However, depressed ST segments",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      negative T waves in leads with negative QRS (\"negative QRS-T\" concordance) are generally abnormal, and may be a sign of underlying ischemia.",
"     </li>",
"     <li>",
"      The appearance of LBBB may change the mean QRS axis in the frontal plane to the right, to the left, or to a superior, in some cases in a rate-dependent manner.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H188055\">",
"    <span class=\"h2\">",
"     Other diagnostic considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiographic changes in LBBB can cause diagnostic problems in a variety of clinical conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventricular hypertrophy &mdash; The diagnosis of left ventricular hypertrophy (LVH) can only be established by echocardiography in the setting of LBBB since the two disorders produce similar ECG changes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The unmasking of left ventricular forces in LBBB (due to lack of counteracting right ventricular forces) results in increased QRS voltage in the leads used for the voltage criteria for LVH.",
"     </li>",
"     <li>",
"      The ST-T vectors in both LVH and LBBB are directed opposite to the QRS vector.",
"      <br/>",
"      <br/>",
"      The diagnostic issues are different in right ventricular hypertrophy (RVH). This disorder may cause the leftward directed initial vector characteristic of LBBB to shift to the right, resulting in \"pseudonormalization\" of the initial vector and the reappearance of q waves in I, aVL, and V6. Echocardiography can be used to determine RVH and ventricular function in this setting. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27204?source=see_link\">",
"       \"ECG tutorial: Chamber enlargement and hypertrophy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myocardial ischemia &mdash; LBBB masks the ability to identify ischemia during exercise because of the associated ST and T wave abnormalities; as a result, exercise perfusion imaging or echocardiography is usually preferred when such patients are evaluated for CHD. It has been suggested that ST segment changes of &ge;0.5 mm from baseline in leads II and AVF are predictive of ischemia in the setting of left bundle branch block [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/26\">",
"       26",
"      </a>",
"      ]. However, this observation does not change the recommendation to use other exercise modalities. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11017?source=see_link\">",
"       \"Electrocardiographic changes during exercise ECG testing\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute myocardial infarction &mdash; LBBB complicates and often prevents the electrocardiographic diagnosis of acute myocardial infarction. This important issue is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9431?source=see_link\">",
"       \"Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H618508\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While LBBB has a fairly characteristic appearance on ECG, there are other conditions in which the ECG may have a similar appearance that need to be excluded prior to the diagnosis of LBBB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175690\">",
"    <span class=\"h2\">",
"     Incomplete LBBB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incomplete LBBB is characterized by a QRS duration of 0.10 to 0.12 sec, a diminutive or absent q in I and V6 that is frequently replaced by a slurred initial upstroke (pseudo-delta wave), a QRS morphology reminiscent of complete LBBB, a delayed intrinsicoid deflection (time from beginning of QRS to its maximal amplitude in V6), and usually increased voltage. Canine studies suggest that incomplete LBBB may be a form of left septal (median) fascicular block [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175773\">",
"    <span class=\"h2\">",
"     Ventricular tachycardia and accelerated idioventricular rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the dominant ventricular rhythm originates from a pacemaker in the ventricle, the QRS will be widened and can have the appearance of a LBBB. However, both ventricular tachycardia (heart rate greater than 100 beats per minute) (",
"    <a class=\"graphic graphic_waveform graphicRef63176 \" href=\"mobipreview.htm?28/0/28680\">",
"     figure 3",
"    </a>",
"    ) and accelerated idioventricular rhythm (heart rate between 60 and 100 beats per minute) (",
"    <a class=\"graphic graphic_waveform graphicRef52385 \" href=\"mobipreview.htm?39/57/40856\">",
"     waveform 2",
"    </a>",
"    ) are associated with atrioventricular (AV) dissociation, which should distinguish the rhythm from a supraventricular rhythm with aberrant conduction seen with RBBB. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/8/43144?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia: Diagnosis and evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1942?source=see_link&amp;anchor=H11#H11\">",
"     \"ECG tutorial: Ventricular arrhythmias\", section on 'Accelerated idioventricular rhythm'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175780\">",
"    <span class=\"h2\">",
"     Ventricular pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular pacing from the right ventricle typically results in a QRS complex resembling that seen with LBBB on the surface ECG. In nearly all patients, however, the presence of pacemaker spikes preceding the QRS complex differentiates a paced complex from LBBB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1390387068\">",
"    <span class=\"h2\">",
"     Ventricular pre-excitation (Wolff-Parkinson-White syndrome)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients with manifest right-sided accessory pathways, the pre-excitation pattern can mimic LBBB. In WPW, however, the PR interval is typically short, which is generally not the case with LBBB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis in patients with LBBB is related largely to the type and severity of any concurrent underlying heart disease and to the possible presence of other conduction disturbances. As an example, patients who also have type II second degree atrioventricular (AV) block or multi-fascicular block generally have more significant myocardial disease and a guarded prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/998?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type II\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/62/12261?source=see_link\">",
"     \"Course and treatment of chronic bifascicular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;LBBB appears to have a minimal effect on outcomes in younger, apparently healthy subjects, while LBBB in older individuals has been associated with an increase in mortality. Two large cohorts of younger asymptomatic persons have reported no increase in mortality in subjects with LBBB, while two other smaller cohorts have reported increases in sudden cardiac death and overall mortality among those with LBBB.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the cohort of 237,000 healthy young men discussed above, the presence of LBBB was not associated with cardiovascular disease or an increase in mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, in a cohort of 110,000 subjects discussed above, the development of LBBB was associated with a higher incidence of subsequent cardiovascular disease without any increase in subsequent mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, among 53,377 women without cardiovascular disease at baseline (excluding those with RBBB) who participated in the Women's Health Initiative trial, there was a significantly greater risk of death from coronary heart disease (adjusted hazard ratio [HR] 2.17, 95% CI 1.37-3.43) and a trending toward higher death from any cause (adjusted HR 1.18, 95% CI 0.90-1.55) among women with LBBB compared with no BBB [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, in a Swedish primary prevention study that followed 7392 middle-aged men for 28 years, a higher mortality rate was demonstrated among the 46 men (0.6 percent) with LBBB [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/28\">",
"       28",
"      </a>",
"      ]. Compared to men without bundle branch block, those with LBBB had significant increases in progression to high-degree AV block (adjusted hazard ratio [HR] 12.9, 95% CI 4.1 to 40.2) and all-cause mortality (adjusted HR 1.9, 95% CI 1.2 to 3.0) that was primarily due to out-of-hospital sudden death. The findings in the Swedish cohort are consistent with those seen in a cohort of 3983 asymptomatic Canadian men, 29 (0.7 percent) of whom developed LBBB during 30 years of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/29\">",
"       29",
"      </a>",
"      ]. The presence of LBBB was associated with a higher mortality and a 10-fold increase in sudden death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Patients with coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;LBBB is an independent predictor of all-cause mortality in patients with known or suspected coronary heart disease (CHD). This has been illustrated in several studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 7073 adults referred for nuclear exercise testing, 2 percent of the subjects had LBBB [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/30\">",
"       30",
"      </a>",
"      ]. After a mean follow-up of nearly seven years, those with LBBB had a greater mortality than those without LBBB (24 versus 11 percent; adjusted HR 1.5, 95% CI 1.1 to 2.0).",
"     </li>",
"     <li>",
"      In a post-hoc analysis of the 15,609 subjects with known CHD enrolled in the Coronary Artery Surgery Study (CASS), the presence of LBBB was associated with a more than fivefold increase in mortality after two years of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Heart Outcomes Prevention Evaluation (HOPE) cohort of 9541 patients with cardiovascular disease or diabetes in the absence of heart failure, the presence of LBBB was associated with a significantly higher risk for major cardiovascular events, cardiovascular death, heart failure, sudden death, and all-cause mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 12,354 women with cardiovascular disease (excluding those with RBBB) who participated in the Women's Health Initiative trial, there was a significantly greater risk of death from coronary heart disease (adjusted HR 2.92, 95% CI 2.08-4.08) and death from any cause (adjusted HR 1.43, 95% CI 1.11-1.83) among women with LBBB compared with no BBB [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, individuals with type II diabetes mellitus and LBBB have more severe and extensive CHD and advanced left ventricular dysfunction as compared with diabetics without LBBB and in individuals with isolated LBBB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13896937\">",
"    <span class=\"h2\">",
"     Patients with acute myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of LBBB is associated with higher short-term and long-term mortality following an acute myocardial infarction (MI). In addition, the presence of LBBB in a patient presenting with chest discomfort can delay or complicate the diagnosis of acute myocardial infarction (MI). Both of these situations are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9431?source=see_link\">",
"     \"Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4282?source=see_link&amp;anchor=H18#H18\">",
"     \"Conduction abnormalities after myocardial infarction\", section on 'Bundle branch block'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Patients with heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even in the absence of associated structural heart disease, LBBB is associated with dyssynchronous left ventricular activation, which reduces the efficiency of left ventricular contraction. The magnitude of the effect on left ventricular dyssynchrony was illustrated in a report in which 18 patients with isolated LBBB were compared with 10 normal controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/34\">",
"     34",
"    </a>",
"    ]. Isolated LBBB was associated with dyssynchronous contraction and a significantly lower left ventricular ejection fraction than the controls (54 versus 62 percent, respectively).",
"   </p>",
"   <p>",
"    The adverse effect of ventricular dyssynchrony due to LBBB is more pronounced in the presence of heart failure, possibly even serving as a primary cause of heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/35\">",
"     35",
"    </a>",
"    ]. Several studies have reported that LBBB is an independent risk factor for mortality in patients with heart failure and is associated with increased all-cause mortality and sudden death at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. However, one study in hospitalized heart failure patients did not find an association with LBBB and longer-term mortality over four years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Worse outcomes in heart-failure patients with LBBB may be expected due to dyssynchronous left ventricular activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. This observation provides the rationale for the use of cardiac resynchronization therapy with biventricular pacing in patients with heart failure who have an intraventricular conduction delay, primarily due to LBBB. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/36/10823?source=see_link\">",
"     \"Rationale for and mechanisms of benefit of cardiac resynchronization therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Exercise-induced LBBB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise-induced LBBB occurs transiently in approximately 0.5 percent of patients undergoing an exercise stress test. The prognostic value of exercise-induced LBBB was long debated. However, exercise-induced LBBB appears to be predictive of higher rates of mortality and cardiac events. In one study of 17,277 exercise stress tests, during which 70 episodes of exercise-induced LBBB occurred, death from any cause and major cardiac events were significantly more common in the group with exercise-induced LBBB (",
"    <a class=\"graphic graphic_figure graphicRef55830 \" href=\"mobipreview.htm?41/60/42957\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11017?source=see_link\">",
"     \"Electrocardiographic changes during exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Patients undergoing noncardiac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients undergoing noncardiac surgery, the presence of a LBBB is not associated with an increase in postoperative cardiac complications but is associated with a nonsignificant increase in perioperative mortality as a result of noncardiovascular complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=see_link&amp;anchor=H6#H6\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\", section on 'Resting electrocardiogram'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When LBBB is present, patients should be evaluated for hypertension, coronary disease, and other disorders that have been associated with LBBB (eg, myocarditis, valvular heart disease, cardiomyopathies). In most patients, this can be accomplished with a careful history and physical examination. Cardiac resynchronization therapy is indicated for the treatment of heart failure in NYHA III or IV patients with a LBBB and reduced left ventricular ejection fraction (LVEF) &lt;35 percent, and it may prevent progression of heart failure in less symptomatic patients (MADIT-CRT). Therefore an assessment of LVEF, usually with echocardiography, is warranted to identify these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/43\">",
"     43",
"    </a>",
"    ]. Focused additional testing (ie, stress testing with imaging) may be indicated for a subset of patients directed by findings from the history, exam, or other data. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/4/28743?source=see_link\">",
"     \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43081?source=see_link&amp;anchor=H9#H9\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\", section on 'LBBB or paced ventricular rhythm'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=see_link&amp;anchor=H30#H30\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\", section on 'Left bundle branch block'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175863\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For asymptomatic patients with an isolated LBBB and no other evidence of cardiac disease, no specific therapy is required. However, permanent pacemaker insertion is indicated for patients who develop symptomatic conduction system disturbances, such as third degree or Mobitz type II second degree AV block, which is not associated with a reversible or transient condition. Patients with LBBB and syncope felt to be cardiac in nature may also be considered for treatment with a permanent pacemaker. In addition, as stated above, patients with LBBB and moderately to severely reduced LVEF may be considered for treatment with cardiac resynchronization therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39784/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. These are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15285?source=see_link\">",
"     \"Third degree (complete) atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/998?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type II\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On rare occasions, insertion of a temporary pacemaker may be indicated for patients with LBBB. A temporary pacemaker may be considered for a patient undergoing right heart catheterization because of the potential for transient complete heart block associated with catheter manipulation. Temporary pacing is also indicated for a LBBB in association with an acute myocardial infarction, particularly when a first degree AV block is also present. The management of patients with a LBBB who have a myocardial infarction and those undergoing surgery is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=see_link\">",
"     \"Temporary cardiac pacing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4282?source=see_link\">",
"     \"Conduction abnormalities after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3371009\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left bundle branch block (LBBB) results when normal electrical activity in the His-Purkinje system is interrupted, thereby altering the normal sequence of activation, resulting in the characteristic electrocardiographic (ECG) appearance of a widened QRS complex and changes in the directional vectors of the R and S waves (",
"      <a class=\"graphic graphic_waveform graphicRef61594 \" href=\"mobipreview.htm?42/28/43466\">",
"       waveform 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H618500\">",
"       'Electrocardiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The bundle of His divides at the juncture of the fibrous and muscular boundaries of the interventricular septum into the right and left bundle branches. The left bundle branch penetrates the membranous portion of the interventricular septum under the aortic ring and then divides into several fairly discrete branches, receiving most of its blood supply for the left anterior descending coronary artery. (See",
"      <a class=\"local\" href=\"#H618484\">",
"       'Anatomy and electrophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of LBBB, which appears to increase with age, has been estimated between 0.2 to 1.1 percent of the general population. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various clinical conditions are associated with the development of LBBB, although LBBB most commonly results not from a single clinical entity but rather from slowly progressive degenerative disease involving the conduction system. LBBB may result following an acute myocardial insult such as myocardial ischemia, myocardial infarction, or myocarditis. In addition, LBBB may be functional as a result of a long preceding R-R interval following by a short cycle (\"rate-related bundle branch block\"). (See",
"      <a class=\"local\" href=\"#H175977\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The electrocardiographic features of the QRS complex which define LBBB in adults include QRS duration greater than or equal to 120 msec; broad notched or slurred R wave in leads I, aVL, V5, and V6 and an occasional RS pattern in V5 and V6; absent q waves in leads I, V5, and V6; R peak time greater than 60 ms in leads V5 and V6 but normal in leads V1, V2, and V3; and ST and T waves usually opposite in direction to QRS complex. (See",
"      <a class=\"local\" href=\"#H618500\">",
"       'Electrocardiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LBBB interferes with the correct ECG-based diagnoses of ventricular hypertrophy, myocardial ischemia, and acute myocardial infarction. (See",
"      <a class=\"local\" href=\"#H188055\">",
"       'Other diagnostic considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ventricular rhythms and ventricular pacing, conditions in which the QRS complex has a similar morphology to LBBB, need to be excluded prior to making the diagnosis of LBBB. (See",
"      <a class=\"local\" href=\"#H618508\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis in patients with LBBB is related largely to the type and severity of any concurrent underlying heart disease and to the possible presence of other conduction disturbances:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among asymptomatic patients, LBBB appears to have minimal effect on outcomes in younger, apparently healthy subjects, while LBBB in older individuals has been associated with an increase in mortality. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Asymptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LBBB is an independent predictor of all-cause mortality in patients with known or suspected coronary heart disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Patients with coronary heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of LBBB is associated with higher short-term and long-term mortality following a myocardial infarction. (See",
"      <a class=\"local\" href=\"#H13896937\">",
"       'Patients with acute myocardial infarction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"       \"Overview of the acute management of ST elevation myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4282?source=see_link&amp;anchor=H18#H18\">",
"       \"Conduction abnormalities after myocardial infarction\", section on 'Bundle branch block'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      LBBB is an independent risk factor for mortality in patients with heart failure and is associated with increased all-cause mortality and sudden death at one year. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Patients with heart failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with chest discomfort and LBBB, the diagnosis of acute myocardial ischemia or infarction may be delayed due to the challenges of interpreting the ECG changes. (See",
"      <a class=\"local\" href=\"#H13896937\">",
"       'Patients with acute myocardial infarction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When LBBB is present, patients should be evaluated for hypertension, coronary disease, and other disorders that have been associated with LBBB (eg, myocarditis, valvular heart disease, cardiomyopathies). In most patients, this can be accomplished with a careful history and physical examination. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For asymptomatic patients with an isolated LBBB and no other evidence of cardiac disease, no specific therapy is required. However, permanent pacemaker insertion is indicated for patients with LBBB who develop symptomatic conduction system disturbances, such as third degree or type II second degree AV block, which is not associated with a reversible or transient condition. (See",
"      <a class=\"local\" href=\"#H175863\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27463?source=see_link\">",
"       \"Indications for permanent cardiac pacing\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Tawara S. Das Reizleitungssystem des S&auml;uegetierherzens. Gustav Fischer, Jena 1906.",
"    </li>",
"    <li>",
"     Rosenbaum M, Elizari MV, Lazzari JO. The Hemiblocks. Tampa Tracings, Tampa 1970.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/3\">",
"      Uhley HN. Some controversy regarding the peripheral distribution of the conduction system. Am J Cardiol 1972; 30:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/4\">",
"      Hecht HH, Kossmann CE, Childers RW, et al. Atrioventricular and intraventricular conduction. Revised nomenclature and concepts. Am J Cardiol 1973; 31:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/5\">",
"      Demoulin JC, Kulbertus HE. Histopathological examination of concept of left hemiblock. Br Heart J 1972; 34:807.",
"     </a>",
"    </li>",
"    <li>",
"     Davies MJ, Anderson RH, Becker AE. The Conduction System of the Heart, Butterworth, London 1983.",
"    </li>",
"    <li>",
"     Josephson ME. Clinical Cardiac Electrophysiology: Techniques and Interpretations, 2nd ed, Lea &amp; Febiger, Philadelphia 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/8\">",
"      Sarter BH, Hook BG, Callans DJ, Marchlinski FE. Effect of bundle branch block on local electrogram morphologic features: implications for arrhythmia diagnosis by stored electrogram analysis. Am Heart J 1996; 131:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/9\">",
"      Fung JW, Yu CM, Yip G, et al. Variable left ventricular activation pattern in patients with heart failure and left bundle branch block. Heart 2004; 90:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/10\">",
"      RODSTEIN M, GUBNER R, MILLS JP, et al. A mortality study in bundle branch block. AMA Arch Intern Med 1951; 87:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/11\">",
"      Siegman-Igra Y, Yahini JH, Goldbourt U, Neufeld HN. Intraventricular conduction disturbances: a review of prevalence, etiology, and progression for ten years within a stable population of Israeli adult males. Am Heart J 1978; 96:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/12\">",
"      OSTRANDER LD Jr, BRANDT RL, KJELSBERG MO, EPSTEIN FH. ELECTROCARDIOGRAPHIC FINDINGS AMONG THE ADULT POPULATION OF A TOTAL NATURAL COMMUNITY, TECUMSEH, MICHIGAN. Circulation 1965; 31:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/13\">",
"      HISS RG, LAMB LE. Electrocardiographic findings in 122,043 individuals. Circulation 1962; 25:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/14\">",
"      Zhang ZM, Rautaharju PM, Soliman EZ, et al. Mortality risk associated with bundle branch blocks and related repolarization abnormalities (from the Women's Health Initiative [WHI]). Am J Cardiol 2012; 110:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/15\">",
"      Eriksson P, Hansson PO, Eriksson H, Dellborg M. Bundle-branch block in a general male population: the study of men born 1913. Circulation 1998; 98:2494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/16\">",
"      Imanishi R, Seto S, Ichimaru S, et al. Prognostic significance of incident complete left bundle branch block observed over a 40-year period. Am J Cardiol 2006; 98:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/17\">",
"      Rotman M, Triebwasser JH. A clinical and follow-up study of right and left bundle branch block. Circulation 1975; 51:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/18\">",
"      LAMB LE, KABLE KD, AVERILL KH. Electrocardiographic findings in 67,375 asymptomatic subjects. V. Left bundle branch block. Am J Cardiol 1960; 6:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/19\">",
"      Schneider JF, Thomas HE Jr, Kreger BE, et al. Newly acquired left bundle-branch block: the Framingham study. Ann Intern Med 1979; 90:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/20\">",
"      Fahy GJ, Pinski SL, Miller DP, et al. Natural history of isolated bundle branch block. Am J Cardiol 1996; 77:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/21\">",
"      Pryor R, Blount SG Jr. The clinical significance of true left axis deviation. Left intraventricular blocks. Am Heart J 1966; 72:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/22\">",
"      LEV M. ANATOMIC BASIS FOR ATRIOVENTRICULAR BLOCK. Am J Med 1964; 37:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/23\">",
"      Ohmae M, Rabkin SW. Hyperkalemia-induced bundle branch block and complete heart block. Clin Cardiol 1981; 4:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/24\">",
"      Bashour T, Hsu I, Gorfinkel HJ, et al. Atrioventricular and intraventricular conduction in hyperkalemia. Am J Cardiol 1975; 35:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/25\">",
"      Surawicz B, Childers R, Deal BJ, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2009; 53:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/26\">",
"      Ibrahim NS, Abboud G, Selvester RS, et al. Detecting exercise-induced ischemia in left bundle branch block using the electrocardiogram. Am J Cardiol 1998; 82:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/27\">",
"      Dabrowska B, Ruka M, Walczak E. The electrocardiographic diagnosis of left septal fascicular block. Eur J Cardiol 1978; 6:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/28\">",
"      Eriksson P, Wilhelmsen L, Rosengren A. Bundle-branch block in middle-aged men: risk of complications and death over 28 years. The Primary Prevention Study in G&ouml;teborg, Sweden. Eur Heart J 2005; 26:2300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/29\">",
"      Rabkin SW, Mathewson FA, Tate RB. Natural history of left bundle-branch block. Br Heart J 1980; 43:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/30\">",
"      Hesse B, Diaz LA, Snader CE, et al. Complete bundle branch block as an independent predictor of all-cause mortality: report of 7,073 patients referred for nuclear exercise testing. Am J Med 2001; 110:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/31\">",
"      Freedman RA, Alderman EL, Sheffield LT, et al. Bundle branch block in patients with chronic coronary artery disease: angiographic correlates and prognostic significance. J Am Coll Cardiol 1987; 10:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/32\">",
"      Sumner G, Salehian O, Yi Q, et al. The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial. J Cardiovasc Electrophysiol 2009; 20:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/33\">",
"      Ozeke O, Aras D, Deveci B, et al. Comparison of presence and extent of coronary narrowing in patients with left bundle branch block without diabetes mellitus to patients with and without left bundle branch block but with diabetes mellitus. Am J Cardiol 2006; 97:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/34\">",
"      Grines CL, Bashore TM, Boudoulas H, et al. Functional abnormalities in isolated left bundle branch block. The effect of interventricular asynchrony. Circulation 1989; 79:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/35\">",
"      Huvelle E, Fay R, Alla F, et al. Left bundle branch block and mortality in patients with acute heart failure syndrome: a substudy of the EFICA cohort. Eur J Heart Fail 2010; 12:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/36\">",
"      Baldasseroni S, Opasich C, Gorini M, et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J 2002; 143:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/37\">",
"      McCullough PA, Hassan SA, Pallekonda V, et al. Bundle branch block patterns, age, renal dysfunction, and heart failure mortality. Int J Cardiol 2005; 102:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/38\">",
"      Barsheshet A, Goldenberg I, Garty M, et al. Relation of bundle branch block to long-term (four-year) mortality in hospitalized patients with systolic heart failure. Am J Cardiol 2011; 107:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/39\">",
"      Auricchio A, Fantoni C, Regoli F, et al. Characterization of left ventricular activation in patients with heart failure and left bundle-branch block. Circulation 2004; 109:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/40\">",
"      Das MK, Cheriparambil K, Bedi A, et al. Prolonged QRS duration (QRS &gt;/=170 ms) and left axis deviation in the presence of left bundle branch block: A marker of poor left ventricular systolic function? Am Heart J 2001; 142:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/41\">",
"      Grady TA, Chiu AC, Snader CE, et al. Prognostic significance of exercise-induced left bundle-branch block. JAMA 1998; 279:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/42\">",
"      Dorman T, Breslow MJ, Pronovost PJ, et al. Bundle-branch block as a risk factor in noncardiac surgery. Arch Intern Med 2000; 160:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/43\">",
"      Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39784/abstract/44\">",
"      Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010; 363:2385.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 914 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F93BED5DA7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_54_39784=[""].join("\n");
var outline_f38_54_39784=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3371009\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H618484\">",
"      ANATOMY AND ELECTROPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175255\">",
"      Anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175262\">",
"      Blood supply",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175319\">",
"      Electrophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175977\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175985\">",
"      Structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176001\">",
"      Functional LBBB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H618500\">",
"      ELECTROCARDIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H188055\">",
"      Other diagnostic considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H618508\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175690\">",
"      Incomplete LBBB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175773\">",
"      Ventricular tachycardia and accelerated idioventricular rhythm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175780\">",
"      Ventricular pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1390387068\">",
"      Ventricular pre-excitation (Wolff-Parkinson-White syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13896937\">",
"      Patients with acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Exercise-induced LBBB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Patients undergoing noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175863\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3371009\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/914\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/914|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/52/43841\" title=\"figure 1\">",
"      Normal conduction system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/44/22213\" title=\"figure 2\">",
"      Coronary artery anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/60/42957\" title=\"figure 4\">",
"      Exercise-induced LBBB and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/914|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?28/0/28680\" title=\"figure 3\">",
"      ECG Monomorphic VT tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?42/28/43466\" title=\"waveform 1\">",
"      Left bundle branch block 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?39/57/40856\" title=\"waveform 2\">",
"      ECG Accelerated idioventricular rhythm tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41637?source=related_link\">",
"      Bundle branch reentrant ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4282?source=related_link\">",
"      Conduction abnormalities after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/62/12261?source=related_link\">",
"      Course and treatment of chronic bifascicular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27204?source=related_link\">",
"      ECG tutorial: Chamber enlargement and hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22038?source=related_link\">",
"      ECG tutorial: Intraventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35558?source=related_link\">",
"      ECG tutorial: Miscellaneous diagnoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1942?source=related_link\">",
"      ECG tutorial: Ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11017?source=related_link\">",
"      Electrocardiographic changes during exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9431?source=related_link\">",
"      Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26858?source=related_link\">",
"      Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/36/10823?source=related_link\">",
"      Rationale for and mechanisms of benefit of cardiac resynchronization therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/998?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/4/28743?source=related_link\">",
"      Stress testing in patients with left bundle branch block or a paced ventricular rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/8/43144?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia: Diagnosis and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=related_link\">",
"      Temporary cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15285?source=related_link\">",
"      Third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43081?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_54_39785="Types of wound healing";
var content_f38_54_39785=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Types of wound healing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 564px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Smeltzer SC, Hinkle JL, Cheever KH. Brunner and Suddarth's Textbook of Medical Surgical Nursing, 12th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_54_39785=[""].join("\n");
var outline_f38_54_39785=null;
var title_f38_54_39786="Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma";
var content_f38_54_39786=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/54/39786/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/54/39786/contributors\">",
"     Steven Horwitz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/54/39786/contributors\">",
"     Joachim Yahalom, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/54/39786/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/54/39786/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/54/39786/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/54/39786/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/54/39786/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hodgkin lymphoma (HL, formerly called Hodgkin's disease) is a group of cancers characterized by malignant Reed-Sternberg cells in an appropriate reactive cellular background. HL tends to arise within lymph node areas and to spread in an orderly fashion to contiguous areas of lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/1\">",
"     1",
"    </a>",
"    ]. Once the diagnosis of HL has been established, subsequent therapy is based upon the stage of the disease, as currently defined by the Cotswolds classification (",
"    <a class=\"graphic graphic_table graphicRef66651 \" href=\"mobipreview.htm?19/23/19836\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13512?source=see_link\">",
"     \"Overview of the treatment of classical Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this discussion, advanced stage HL refers to clinical stage (CS) III and IV disease. CS III describes involvement of lymph nodes or lymphoid structures on both sides of the diaphragm. CS IV refers to diffuse or disseminated involvement of one or more extranodal organs or tissues, with or without lymph node disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial treatment of advanced stage HL will be reviewed here. The following are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The evaluation of the patient before, during, and after therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30007?source=see_link\">",
"       \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=see_link\">",
"       \"Long-term follow-up of the patient with classical Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The treatment of favorable early stage HL. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11770?source=see_link\">",
"       \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The treatment of unfavorable early stage HL. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27496?source=see_link\">",
"       \"Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The treatment or relapsed or refractory HL. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/17/37145?source=see_link\">",
"       \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7784?source=see_link\">",
"       \"Relapse of classical Hodgkin lymphoma after initial radiotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The treatment of nodular lymphocyte predominant HL. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/45/34520?source=see_link\">",
"       \"Treatment of nodular lymphocyte-predominant Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of a patient with HL must establish the precise histologic subtype, the extent and sites of disease, and the performance status of the patient. This evaluation is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29206?source=see_link\">",
"     \"Initial evaluation and diagnosis of Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     International prognostic score",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced stage HL can be further divided into prognostic groups using the international prognostic score (IPS), which incorporates seven factors (ie, serum albumin, hemoglobin, gender, age, stage, white blood cell count, and absolute lymphocyte count) to delineate six prognostic groups with very different rates of freedom from progression at five years, demonstrating that even among those with advanced stage disease the prognosis is quite variable (",
"    <a class=\"graphic graphic_table graphicRef76219 \" href=\"mobipreview.htm?11/50/12077\">",
"     table 2",
"    </a>",
"    )(",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?4/32/4609?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/37/14935?source=see_link&amp;anchor=H9398231#H9398231\">",
"     \"Staging and prognosis of Hodgkin lymphoma\", section on 'International Prognostic Score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination chemotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    (ABVD) continued for six (and occasionally eight) cycles based on disease response is the preferred therapy for most patients with advanced HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. BEACOPP or escalated BEACOPP (bleomycin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , doxorubicin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) and Stanford V (doxorubicin, vinblastine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    , vincristine, bleomycin, etoposide, and prednisone) are acceptable alternatives (",
"    <a class=\"graphic graphic_table graphicRef74186 \" href=\"mobipreview.htm?7/60/8142\">",
"     table 3",
"    </a>",
"    ). A key factor in the success of these regimens appears to be the incorporation of both an anthracycline and an alkylating agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/6-9\">",
"     6-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ABVD has been the standard regimen used for advanced HL for several decades (",
"      <a class=\"graphic graphic_table graphicRef68131 \" href=\"mobipreview.htm?0/59/958\">",
"       table 4",
"      </a>",
"      ). ABVD administration is repeated every 14 days in 28-day cycles: two administrations are considered one cycle. Patients are monitored with imaging studies for response during treatment and receive two cycles of chemotherapy beyond best response, with six cycles considered to be a full course of chemotherapy and eight cycles the maximal number of courses. As such, the total time of chemotherapy ranges from 24 to 32 weeks. Long term toxicities include cardiopulmonary toxicity, which is more frequently seen in children and in combination with mediastinal irradiation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'ABVD chemotherapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      BEACOPP (standard",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      escalated) is being increasingly used worldwide and may have particular utility in patients with a high international prognostic score (eg, IPS of 4 or greater). BEACOPP is administered on days 1 and 8 of a 21-day cycle with scheduled growth factor support for a total time of chemotherapy ranging from 18 to 24 weeks. Eight cycles of escalated BEACOPP was initially shown to be superior to standard (baseline) BEACOPP or",
"      <span class=\"nowrap\">",
"       COPP/ABVD.",
"      </span>",
"      Six cycles of escalated BEACOPP may be more effective and less toxic. Alternatively, four cycles of escalated BEACOPP may be followed by four cycles of either escalated or standard-dose BEACOPP, depending upon the response to the first four cycles. When compared with ABVD, BEACOPP is associated with higher rates of toxicity including reversible bone marrow suppression, secondary malignancies, and sterility. Toxicities are particularly severe in the elderly, making it an inappropriate treatment for patients over 60 years. It is unknown how BEACOPP affects the ability to provide effective salvage therapy, such as autologous hematopoietic cell transplantation, to patients who relapse. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'BEACOPP chemotherapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Stanford V is a combined modality treatment that incorporates radiation therapy (RT) for the great majority of patients. Chemotherapy is administered weekly for a total of 12 weeks. RT is initiated one to three weeks after the completion of chemotherapy and delivered to all sites of disease 5 cm or larger at diagnosis and to areas of macroscopic splenic involvement. The main toxicities are neutropenia and constipation. No cases of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      lung toxicity, radiation pneumonitis, secondary leukemia or lymphoma have been reported. Fertility appears to be preserved. While randomized studies have failed to show any superiority over ABVD, this regimen remains an option for those patients without high risk features who would be expected to benefit from the addition of radiation therapy regardless of the chemotherapy regimen chosen, or for patients for whom lower doses of bleomycin or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      or a shorter length of treatment are important considerations. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Stanford V'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H19\">",
"       'Is there a role for radiation?'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the increasing availability of guidelines for the treatment of Hodgkin lymphoma, there must remain room for individualization of treatment. In particular, patient preference must be considered with different treatment options, some of which result in a higher recurrence risk at the gain of less toxic initial treatment. Treatment should also be individualized when a particular approach might result in a higher risk of acute",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    late complications. For most patients with advanced stage HL, we suggest treatment with ABVD, although Stanford V and BEACOPP are reasonable alternatives, as discussed below. Stanford V may be chosen because of its short administration schedule (12 versus 24 to 32 weeks with ABVD), decreased pulmonary toxicity (total",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    dose is 25 percent of 6 cycles of ABVD) and reduced dosing of anthracycline (total",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    dose is 150",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    versus 300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for six cycles of ABVD). Escalated BEACOPP is an increasingly common choice. The greatest potential benefit when compared with",
"    <span class=\"nowrap\">",
"     COPP/ABVD",
"    </span>",
"    was seen in those patients with an IPS of 4 or greater, despite increased side effects. Details on the efficacy and toxicities associated with these regimens are presented in detail in the sections that follow.",
"   </p>",
"   <p>",
"    Phase III trials examining alternating therapy with ABVD and other combinations have not shown improved outcome and have, at times, demonstrated increased toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/2,10,11\">",
"     2,10,11",
"    </a>",
"    ]. In addition, randomized trials have demonstrated that ABVD is both more effective and less toxic than the MOPP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) regimen, which had been the first chemotherapy regimen developed to cure advanced stage HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/12-19\">",
"     12-19",
"    </a>",
"    ]. ABVD is also significantly less toxic and equally effective to hybrid regimens such as MOPP-ABV, in which patients receive one-half of a cycle of MOPP and one-half of a cycle of ABVD without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    within a one-month period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/2,20-24\">",
"     2,20-24",
"    </a>",
"    ]. Regimens that have proven inferior to ABVD include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (EVA) and EVA plus prednisone (VEPA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other abbreviated regimens that have not proven to be superior include VAPEC-B (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ); ChlVPP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    and prednisolone); BCVPP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    , cyclophosphamide, vinblastine, procarbazine, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ); and PACE-BOM (prednisone, doxorubicin, cyclophosphamide, etoposide, bleomycin, vincristine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/28-39\">",
"     28-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     ABVD chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;ABVD (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    ) was originally developed for patients with disease resistant to MOPP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ), but subsequently became the standard initial chemotherapy for patients with HL (",
"    <a class=\"graphic graphic_table graphicRef74186 \" href=\"mobipreview.htm?7/60/8142\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/40\">",
"     40",
"    </a>",
"    ]. ABVD is administered every 14 days in 28-day cycles (",
"    <a class=\"graphic graphic_table graphicRef68131 \" href=\"mobipreview.htm?0/59/958\">",
"     table 4",
"    </a>",
"    ). Patients are monitored with imaging studies for response during treatment and receive two cycles of chemotherapy beyond best response, with six cycles considered to be a minimum and most commonly used duration. As such, the total time of chemotherapy ranges from 24 to 32 weeks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30007?source=see_link\">",
"     \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     ABVD efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 80 percent of patients with advanced stage HL will attain a complete response after treatment with ABVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/19,20,40-45\">",
"     19,20,40-45",
"    </a>",
"    ]. Up to one-quarter of patients will have disease progression requiring further therapy; half of those will have long term survival with autologous hematopoietic cell transplantation. Overall survival rates at 4, 7, and 10 years are approximately 90, 75, and 55 percent, respectively.",
"   </p>",
"   <p>",
"    The efficacy of ABVD has been demonstrated in many prospective trials. These trials have shown ABVD to be superior to MOPP and to have equal efficacy and less toxicity than alternating MOPP-ABVD and",
"    <span class=\"nowrap\">",
"     MOPP/ABV",
"    </span>",
"    hybrids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/2\">",
"     2",
"    </a>",
"    ]. Initial studies comparing ABVD with BEACOPP and Stanford V have demonstrated similar overall survival rates. Trials comparing ABVD with Stanford V and BEACOPP are presented in the sections that describe these regimens. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'BEACOPP efficacy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Stanford V'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As an example, a trial that included 361 patients with advanced HL or relapse after initial radiotherapy randomly assigned treatment with either 6 to 8 cycles of MOPP, 6 to 8 cycles of ABVD, or 12 cycles of MOPP alternating with ABVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/19\">",
"     19",
"    </a>",
"    ]. MOPP alternating with ABVD was as effective but more toxic than ABVD alone. When compared with those who were assigned to MOPP, patients assigned to ABVD demonstrated the following benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher rate of initial complete response (82 versus 67 percent)",
"     </li>",
"     <li>",
"      Less hematologic toxicity",
"     </li>",
"     <li>",
"      A higher rate of failure-free survival at five years (61 versus 50 percent)",
"     </li>",
"     <li>",
"      A better outcome after relapse. Of patients with recurrent disease after ABVD who subsequently received MOPP, 61 percent achieved a second remission; in comparison, only 35 percent of those who suffered relapse after MOPP responded to ABVD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     ABVD toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;ABVD is associated with both acute and long term toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5413363\">",
"    <span class=\"h4\">",
"     Acute",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    acute toxicities seen with ABVD include neutropenia (34 percent),",
"    <span class=\"nowrap\">",
"     nausea/vomiting",
"    </span>",
"    (13 percent), and alopecia (31 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/45\">",
"     45",
"    </a>",
"    ]. Severe myelosuppression is rare when ABVD is administered alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/41\">",
"     41",
"    </a>",
"    ], and the dose-intensity of ABVD can often be maintained at &gt;99 percent without the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Severe infections, anemia, and thrombocytopenia are not common, occurring in 2, 5, and 3 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/45\">",
"     45",
"    </a>",
"    ]. The rate of anticipatory nausea and vomiting has decreased substantially with the development and routine use of potent antiemetic agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     Bleomycin",
"    </a>",
"    -induced pulmonary toxicity may occur quite often (approximately 20 to 30 percent of patients) and usually develops subacutely while on therapy or up to six months after treatment. Bleomycin-induced pulmonary toxicity adversely affects survival in patients who are treated for HL. In one study, it was associated with a mortality rate of 4.2 percent and with a significantly decreased five-year overall survival (63 percent in patients who developed bleomycin-induced pulmonary toxicity as compared with 90 percent in those who are unaffected) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/48\">",
"     48",
"    </a>",
"    ]. The omission of bleomycin in patients who developed bleomycin-induced pulmonary toxicity (either symptomatic or asymptomatic) had no impact on response rates or survival. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Acute reactions to bleomycin, including fever, the hyperpyrexia syndrome, and anaphylactoid reactions have also been described. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link&amp;anchor=H50#H50\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Bleomycin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5413388\">",
"    <span class=\"h4\">",
"     Long-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long term complications of ABVD include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -related pulmonary toxicity and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -associated cardiotoxicity. There does not appear to be an increased rate of myelodysplasia or secondary leukemia, and fertility is preserved in the majority of patients.",
"    <br/>",
"    <br/>",
"    ABVD may result in late bleomycin-related pulmonary toxicity, particularly when used in combination with mediastinal irradiation. Fatal pulmonary complications have occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/19,48,49\">",
"     19,48,49",
"    </a>",
"    ]. Following ABVD, there may be a significant decline in median forced vital capacity and diffusing capacity (DLCO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. The diagnosis and management of bleomycin-induced lung injury is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 60 early-stage patients with HL receiving ABVD with or without mediastinal irradiation, 53 percent reported dyspnea on exertion or cough during ABVD, 37 percent had a significant decline in pulmonary function, and 23 percent required discontinuation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/51\">",
"       51",
"      </a>",
"      ]. At longer follow-up, only one patient reported persistent dyspnea with minimal exertion.",
"     </li>",
"     <li>",
"      In another study of 141 patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      -containing chemotherapy for newly-diagnosed HL, pulmonary toxicity was diagnosed in 25, with a subsequent mortality of 24 percent, all in patients &gt;40 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/48\">",
"       48",
"      </a>",
"      ]. Other reported risk factors for the development of this complication include mediastinal irradiation, treatment with G-CSF, and use in children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/48,50,52-54\">",
"       48,50,52-54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cardiomyopathy is a recognized complication of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    therapy, but is not commonly seen in patients receiving ABVD. Patients who are treated with six cycles of ABVD receive a total doxorubicin dose of 300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ;",
"    </span>",
"    cardiomyopathy is rarely seen in patients who receive a total dose less than 400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    However, ABVD may be associated with a risk of long term cardiac toxicity. A large British study documented that the risk for myocardial infarction after treatment with ABVD alone (without radiotherapy) was 7.8 times higher than that the age adjusted normal population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/55\">",
"     55",
"    </a>",
"    ].Children appear to be more susceptible to doxorubicin cardiotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ABVD does not result in a high incidence of permanent azoospermia or amenorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/41,56,57\">",
"     41,56,57",
"    </a>",
"    ]. In one study, for example, azoospermia and oligospermia after ABVD occurred in 36 and 20 percent of patients, respectively, with recovery to normal values in all cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 15-year cumulative risk of acute myeloid leukemia after ABVD has been estimated to be less than 1 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=see_link&amp;anchor=H7#H7\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\", section on 'Acute leukemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     BEACOPP chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The German Hodgkin's Lymphoma Study Group (GHSG) developed the BEACOPP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) regimen (",
"    <a class=\"graphic graphic_table graphicRef74186 \" href=\"mobipreview.htm?7/60/8142\">",
"     table 3",
"    </a>",
"    ) that is given in standard or escalated doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. When compared with standard ABVD, escalated BEACOPP produces superior progression-free survival rates, but has increased toxicity (ie, neutropenia and infections) and no clear difference in overall survival rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/45,61\">",
"     45,61",
"    </a>",
"    ]. Complete response rates with BEACOPP are approximately 80 to 95 percent with five-year progression-free and overall survival rates of 81 and 92 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple versions of BEACOPP have been developed. Eight cycles of escalated BEACOPP was initially shown to be superior to standard (baseline) BEACOPP or",
"    <span class=\"nowrap\">",
"     COPP/ABVD",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/62\">",
"     62",
"    </a>",
"    ]. In a subsequent randomized trial, compared with eight cycles, six cycles of escalated BEACOPP resulted in superior freedom from treatment failure and overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/63\">",
"     63",
"    </a>",
"    ]. In other studies, four cycles of escalated BEACOPP were administered followed by four cycles of either escalated or standard-dose BEACOPP, depending upon the response to the first four cycles.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Standard-dose BEACOPP (also known as baseline BEACOPP) &mdash; When compared with ABVD and MOPP, dose intensity was increased in the BEACOPP regimen by adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      and increasing the frequency of treatment cycles (from every 28 days to every 21 days), thereby providing more chemotherapy in a shorter time period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Escalated BEACOPP &mdash; Further dose intensification was accomplished with the escalated BEACOPP regimen, which is also repeated at 21-day intervals. This regimen has increased doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (from 25 to 35",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (from 650 to 1250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (from 100 to 200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/62\">",
"       62",
"      </a>",
"      ]. Hematologic growth factor support was added on day 8. [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/65\">",
"       65",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     BEACOPP efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eighty to 95 percent of patients with advanced HL will attain a complete response with BEACOPP. Up to 20 percent (higher rates with baseline BEACOPP than escalated BEACOPP) will have disease progression by five-years and will require further therapy. The overall survival rate at five years is approximately 92 percent. BEACOPP has been compared with other regimens, including",
"    <span class=\"nowrap\">",
"     COPP/ABVD",
"    </span>",
"    and ABVD in randomized, controlled trials. When compared with ABVD, BEACOPP provides better initial tumor control, but no difference in event-free or overall survival when relapsed or refractory disease is managed with high dose chemotherapy followed by autologous stem cell support.",
"   </p>",
"   <p>",
"    Several randomized trials have compared BEACOPP with ABVD-based therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/45,61,62,64-67\">",
"     45,61,62,64-67",
"    </a>",
"    ]. Taken together, these studies demonstrate that BEACOPP is associated with higher response rates and better rates of progression-free survival than those seen with ABVD, but no improvement in overall survival. This was best illustrated in a 2011 meta-analysis that included data from four randomized trials with a total of 2868 adult patients with newly diagnosed advanced stage or unfavorable early stage HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/68\">",
"     68",
"    </a>",
"    ]. BEACOPP resulted in significantly longer progression-free survival (hazard ratio 0.53; 95% CI 0.44-0.64), but no different in overall survival (hazard ratio 0.80; 95% CI 0.59-1.09). BEACOPP was associated with significantly more severe hematologic toxicity, infections, and occurrence of myelodysplastic syndrome and acute myeloid leukemia.",
"   </p>",
"   <p>",
"    It appears that the degree of the progression-free survival benefit may be greatest among the highest risk patients. However, this comes at the cost of increased toxicity with no clear improvement in overall survival when compared with ABVD alone. Initial treatment with BEACOPP exposes approximately 73 percent of patients with advanced stage HL (those cured by ABVD) to excess toxicity that may include such effects as sterility and secondary malignancies. In comparison, initial treatment with ABVD avoids these toxicities in the majority of patients, but requires that approximately one in eight patients proceed to high dose chemotherapy and autologous stem cell rescue at progression, a treatment with potential complications of acute toxic effects, sterility, and secondary malignancies. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'BEACOPP toxicities'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Reducing the number of escalated BEACOPP treatment cycles from eight to six appears to result in superior efficacy and less toxicity. In the GHSG HD15 trial, 2182 adults with newly diagnosed advanced stage HL were randomly assigned therapy with either eight cycles of escalated BEACOPP, six cycles of escalated BEACOPP, or eight cycles of baseline BEACOPP delivered every 14 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/63\">",
"     63",
"    </a>",
"    ]. When compared with eight cycles, six cycles of escalated BEACOPP resulted in higher rates of freedom from treatment failure (89 versus 84 percent) and overall survival (95 versus 92 percent) at five years and less treatment-related toxicity. There was no advantage of baseline BEACOPP delivered every 14 days. It is unknown how six cycles of escalated BEACOPP compares with ABVD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     BEACOPP toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common complications of BEACOPP therapy include bone marrow suppression, infection, nausea, hair loss, second malignancies, and sterility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5413529\">",
"    <span class=\"h4\">",
"     Short term",
"    </span>",
"    &nbsp;&mdash;&nbsp;BEACOPP, especially increased dose BEACOPP, is associated with more acute toxicities than ABVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/62,69\">",
"     62,69",
"    </a>",
"    ]. Patients who received increased dose BEACOPP in clinical trials had a higher incidence of grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    hematologic toxicities, including leukopenia (98 versus 22 percent with ABVD), thrombocytopenia (70 versus 3 percent), and anemia (66 versus 5 percent). Other acute grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    toxicities that occurred in more than 10 percent of patients included infection (22 versus 2 percent with ABVD), nausea (20 versus 13 percent), and hair loss (79 versus 31 percent). The administration of erythropoietin in conjunction with BEACOPP decreases the number of red cell transfusions required during therapy, but has no impact on treatment associated fatigue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The toxicities of BEACOPP are particularly striking in the elderly. Of 42 patients age 66 to 75 who received standard dose BEACOPP, 21 percent died of acute toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5413542\">",
"    <span class=\"h4\">",
"     Long term",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main long term complications of BEACOPP are second malignancies and sterility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/72\">",
"     72",
"    </a>",
"    ]. The following findings have been noted in prospective trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At five years, the rate of secondary acute leukemia was significantly higher with escalated BEACOPP compared with BEACOPP or",
"      <span class=\"nowrap\">",
"       COPP/ABVD",
"      </span>",
"      (2.5 versus 0.6 and 0.4 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/62\">",
"       62",
"      </a>",
"      ]. The rate at 10 years was higher than that at five years only with BEACOPP (1.5 versus 0.6 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At five years, non-Hodgkin lymphoma (NHL) developed in 1.0, 0.9, and 2.7 percent of patients receiving escalated BEACOPP, standard BEACOPP, or",
"      <span class=\"nowrap\">",
"       COPP/ABVD,",
"      </span>",
"      respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/62\">",
"       62",
"      </a>",
"      ]. The frequency of NHL was similar at 10 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At 10 years, the overall rates of secondary malignancy were 6.8, 8.9, and 6.7 percent of patients treated with escalated BEACOPP, baseline BEACOPP, and COPP-ABVD, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The overall issue of secondary malignancies following the treatment of Hodgkin disease is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gonadal toxicity also appears to be a significant risk with BEACOPP regimens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one retrospective analysis, approximately half of the 405 female patients under the age of 40 years at the time of diagnosis treated with escalated BEACOPP and followed for a median of 3.2 years reported permanent amenorrhea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/73\">",
"       73",
"      </a>",
"      ]. A phase II trial found no protection from this chemotherapy-induced gonadal toxicity with the use of either oral contraceptives or GnRH-analogues in young women treated with escalated BEACOPP for advanced-stage HL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/74\">",
"       74",
"      </a>",
"      ]. None of the women in the entire study cohort had preserved ovarian follicle function.",
"     </li>",
"     <li>",
"      Data on gonadal toxicity was reported for 417 male and 232 female survivors of advanced stage HL treated with BEACOPP on the German HD15 trial and followed for a median of four years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/75\">",
"       75",
"      </a>",
"      ]. Women tested for anti-m&uuml;llerian hormone, a marker of ovarian reserve, consistently demonstrated depletion of the ovarian follicle pool suggesting that they would have a poor response to in vitro fertilization. When compared with older women, a higher percentage of women &lt;30 years were able to recover menstrual activity (82 versus 45 percent). While approximately half of female survivors expressed a desire to have children, only 15 percent reported successful pregnancies. The majority (89 percent) of men had evidence of oligospermia, and approximately 20 percent had low testosterone levels (&lt;2.8",
"      <span class=\"nowrap\">",
"       ng/L).",
"      </span>",
"      Twelve men were able to successfully father children, two after natural fertilization and 10 after assisted reproduction.",
"     </li>",
"     <li>",
"      In an evaluation of 38 male patients with advanced stage HL treated with BEACOPP, most had evidence of azoospermia (89 percent) or other forms of dysspermia (11 percent) after completion of therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/76\">",
"       76",
"      </a>",
"      ]. No patient had normozoospermia. There appeared to be no difference in rates of azoospermia between patients treated with standard and escalated BEACOPP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Stanford V",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Stanford V regimen uses a brief intensive chemotherapy regimen (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) combined with radiation therapy (RT) to bulky lymph node sites 5 cm or more in diameter in patients with stage III, stage IV, or bulky mediastinal stage II disease (",
"    <a class=\"graphic graphic_table graphicRef74186 \" href=\"mobipreview.htm?7/60/8142\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66651 \" href=\"mobipreview.htm?19/23/19836\">",
"     table 1",
"    </a>",
"    ). The cumulative doses of doxorubicin, mechlorethamine, and bleomycin are significantly reduced compared with ABVD.",
"   </p>",
"   <p>",
"    Stanford V is preferred by some clinicians because of its short administration schedule (12 versus 24 to 32 weeks), decreased rates of pulmonary toxicity, and good outcomes in single institution, nonrandomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. However, subsequent randomized trials have failed to demonstrate superior outcomes with Stanford V when compared with ABVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/43,44,80,81\">",
"     43,44,80,81",
"    </a>",
"    ]. As such, ABVD remains the standard treatment for most patients with advanced stage HL. Stanford V may be considered as an alternative for patients without high risk features who would be expected to benefit from the addition of radiation therapy regardless of the chemotherapy regimen chosen, patients for whom lower doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    are preferred, and patients requiring a shorter length of treatment.",
"   </p>",
"   <p>",
"    Approximately 60 percent of patients with advanced HL will attain a complete response (CR) or unconfirmed CR after the completion of Stanford V (including radiation when applicable) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/43,44,77-80,82,83\">",
"     43,44,77-80,82,83",
"    </a>",
"    ]. Up to one-quarter will have disease progression by five years and will require further therapy. The overall survival rate at five years is approximately 92 percent.",
"   </p>",
"   <p>",
"    The three randomized phase III trials comparing Stanford V with ABVD have failed to show superiority to ABVD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase",
"      <span class=\"nowrap\">",
"       II/III",
"      </span>",
"      trial from the United Kingdom randomly assigned 520 patients to receive ABVD or Stanford V [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. Involved field RT was administered to patients with initial bulky disease (&gt;5 cm) and to splenic deposits. The protocol was amended partway through the trial to omit radiation for patients who achieved a complete response after ABVD. At a median follow-up of 4.3 years, both treatment arms demonstrated similar rates of overall response (91 versus 92 percent), progression-free survival at five years (74 versus 76 percent), and overall survival at five years (92 versus 90 percent).",
"     </li>",
"     <li>",
"      A phase III trial from Italy randomly assigned 355 patients with stage IIB-IV HL to receive ABVD, a modified Stanford V regimen, or a third combination regimen (MEC) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/80\">",
"       80",
"      </a>",
"      ]. RT was not mandatory in this trial and was administered to 66 and 62 percent of patients assigned to Stanford V and ABVD, respectively. At a median follow-up of 56 months, the five-year failure-free survival rates were 83 percent for ABVD, 85 percent for MEC, and 67 percent for Stanford V. However, with further follow-up, overall survival rates at eight (88, 84, and 77 percent, respectively) and 10 (87, 80, 78 percent, respectively) years were not significantly different [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A large phase III US intergroup trial run by ECOG compared ABVD with Stanford V in 794 patients with locally extensive or advanced stage HL (60 percent had stage III-IV disease) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/85\">",
"       85",
"      </a>",
"      ]. Patients assigned to Stanford V were to receive involved-field RT to all sites &gt;5 cm or for macroscopic splenic disease. Involved-field RT was also incorporated for patients assigned to ABVD with bulky mediastinal disease. At a median follow-up of 6.4 years, Stanford V resulted in the following outcomes when compared with ABVD:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Similar rates of complete response (69 versus 73 percent)",
"     </li>",
"     <li>",
"      Similar rates of severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      short-term toxicity overall, but higher rates of lymphopenia (78 versus 42 percent) and sensory neuropathy (10 versus 4 percent)",
"     </li>",
"     <li>",
"      Similar rates of failure-free (71 versus 74 percent) and overall survival (88 percent each) at five years",
"     </li>",
"     <li>",
"      Lower five-year FFS in high risk patients (&gt;3 risk factors by IPS) (57 percent versus 67 percent)",
"     </li>",
"     <li>",
"      More frequent use of radiation (75 percent versus 41 percent)",
"     </li>",
"     <li>",
"      Less total",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, the data described above suggests that the Stanford V regimen, when administered with RT for bulky disease, provides similar overall response rates and short-term progression-free and overall survival rates to ABVD.",
"   </p>",
"   <p>",
"    The most common non-hematologic short term toxicities with Stanford V include sensory neuropathy (71 percent), motor neuropathy (32 percent), autonomic neuropathy (46 percent),",
"    <span class=\"nowrap\">",
"     nausea/vomiting",
"    </span>",
"    (52 percent), chemical phlebitis (38 percent), and",
"    <span class=\"nowrap\">",
"     myalgias/arthralgias",
"    </span>",
"    (24 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/86\">",
"     86",
"    </a>",
"    ]. The majority of these were mild to moderate (grade",
"    <span class=\"nowrap\">",
"     1/2).",
"    </span>",
"    Severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    neutropenia and anemia are seen in 82 and 60 percent of patients, respectively. The rate of febrile neutropenia without growth factor support is 17 percent.",
"   </p>",
"   <p>",
"    There are limited data on the long term complications of Stanford V. A single institution prospective study of Stanford V with median follow-up of 6.9 years reported five secondary malignancies among a total of 256 patients (all stages included) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Two patients developed breast cancer after mediastinal and axillary radiation while three others developed solid tumors outside of the involved field of radiation. No cases of secondary leukemia or non-Hodgkin lymphomas had occurred. Fertility appears to be frequently preserved. This low rate of long-term toxicity following Stanford V was corroborated by a retrospective analysis from another institution with a median follow-up of 92 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ABVD continues to be the preferred chemotherapy regimen for most patients with HL because of the potential to avoid RT in the 35 to 40 percent of patients who experience a complete response with chemotherapy alone. Stanford V remains an alternative for select individuals in whom a shorter period of treatment (12 versus 24 to 32 weeks), less",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    (one-fourth total dose versus 6 cycles of ABVD), or less anthracycline (one-half total dose versus 6 cycles of ABVD) are important considerations. This regimen also remains an option for patients who will receive preplanned RT after chemotherapy, regardless of response. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Is there a role for radiation?'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13244407\">",
"    <span class=\"h2\">",
"     Is there a role for rituximab?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anti-CD20 monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is incorporated into the treatment of many B-cell non-Hodgkin lymphoma subtypes. While classical HL is thought to be derived from germinal center B cells, expression of CD20 is variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/87\">",
"     87",
"    </a>",
"    ]. The Reed Sternberg (RS) cells generally lack global expression of CD20, but up to 20 to 30 percent of cells within a given case may express CD20 with variable intensity. In addition, the HL stem cell and cells that make up the tumor microenvironment may express CD20. As such, nonrandomized phase II trials have investigated the addition of rituximab to ABVD chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. At present, data are lacking to determine whether the addition of rituximab improves outcomes in this population; however, randomized studies are ongoing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15578?source=see_link&amp;anchor=H17#H17\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\", section on 'Immunophenotype'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     IS THERE A ROLE FOR RADIATION?",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of consolidation radiotherapy (RT) after chemotherapy induction for advanced stage HL is controversial. The addition of radiotherapy to initial chemotherapy appears to improve freedom from progression, but not survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. Proponents advocate its use because the majority of relapses following systemic chemotherapy for HL are in previously involved or unirradiated sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. Opponents of its use question its necessity and raise concerns about the long-term side effects. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Radiation toxicity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most clinicians agree that RT is probably not beneficial and potentially detrimental in patients without initially bulky disease who achieve a complete remission with ABVD and will receive an additional two cycles of ABVD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/37/14935?source=see_link&amp;anchor=H14#H14\">",
"     \"Staging and prognosis of Hodgkin lymphoma\", section on 'Criteria for bulky disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether or not consolidative RT should be administered to patients with initial bulky mediastinal disease (&gt;10 cm or",
"    <span class=\"nowrap\">",
"     &gt;1/3",
"    </span>",
"    the chest diameter) remains an unresolved issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Radiation efficacy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous prospective and retrospective studies have evaluated the use of consolidation radiotherapy (RT) in patients with advanced stage HL with mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/2,92-102\">",
"     2,92-102",
"    </a>",
"    ]. The interpretation of these studies has been controversial. Many randomized trials did not contain adequate numbers of patients to detect a survival benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/90\">",
"     90",
"    </a>",
"    ]. Thus, they suffer from possible false-negative outcomes (type 2 error) due to insufficient power. This problem is magnified in some studies by the attrition of patients who fail to achieve complete remission, or who refuse randomization following chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     After ABVD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for RT after ABVD include initial bulky mediastinal disease (&gt;10 cm or",
"    <span class=\"nowrap\">",
"     &gt;1/3",
"    </span>",
"    the chest diameter)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of residual abnormalities on imaging studies after completion of chemotherapy (ie, partial response, PR). RT is probably not beneficial in patients without initially bulky disease who achieve a complete remission (CR) with ABVD and will receive an additional two cycles of ABVD. A possible exception to this is in patients with nodular sclerosis HL who may have improved tumor control with RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/91\">",
"     91",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'General'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The omission of RT for patients who achieve a CR with ABVD is supported by a phase III European Organisation for Research and Treatment of Cancer (EORTC) trial that randomly assigned 333 patients to consolidation RT or observation after the achievement of a CR with a",
"    <span class=\"nowrap\">",
"     MOPP/ABV",
"    </span>",
"    hybrid regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/103\">",
"     103",
"    </a>",
"    ]. When compared with patients who received RT, patients who did not receive RT had similar rates of event-free survival (77 versus 73 percent) and overall survival (85 versus 78 percent) at eight years. Patients who received RT had a nonsignificant trend towards a higher rate of secondary cancer at eight years (13 versus 6 percent). However, there are several limitations to this trial: the chemotherapy regimen",
"    <span class=\"nowrap\">",
"     (MOPP/ABV",
"    </span>",
"    hybrid) is no longer in use due to its excessive toxicity; most patients received 8 cycles of chemotherapy and still the fraction of patients randomized as CR was only 65 percent, and, most patients with bulky disease were not randomized. It is also unexplained why excess in leukemia cases that was reported only in CR patients who received low-dose radiation consolidation has not been observed in the larger group of partial responders who have all received radiation as well.",
"   </p>",
"   <p>",
"    The use of RT in patients with a partial remission (PR) after ABVD is also supported by the EORTC trial described above. In this same trial, 247 patients achieved a PR after",
"    <span class=\"nowrap\">",
"     MOPP/ABV,",
"    </span>",
"    227 of whom were given consolidation RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/103\">",
"     103",
"    </a>",
"    ]. When compared with those who had achieved a CR after",
"    <span class=\"nowrap\">",
"     MOPP/ABV,",
"    </span>",
"    those patients who received RT after achieving a PR had similar rates of event-free survival (76 percent) and overall survival (84 percent) at eight years. In this trial, response was determined using computed tomography (CT) criteria. It is likely that a percentage of patients who achieve a PR by CT criteria had fibrosis rather than residual HL suggesting that some of these patients were potentially overtreated. Response criteria now incorporate findings from positron emission tomography (PET) scans. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30007?source=see_link&amp;anchor=H1515431811#H1515431811\">",
"     \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\", section on 'Response categories'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bulky mediastinal disease is an adverse prognostic marker in patients with advanced stage HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/104\">",
"     104",
"    </a>",
"    ]. The use of consolidation RT in this group of patients is largely based upon retrospective analyses.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A nonrandomized study of RT embedded within a randomized trial of chemotherapy (ABVD versus two other multidrug regimens) in newly diagnosed advanced stage HL included 222 patients who received RT mostly due to bulky disease or incomplete response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/102\">",
"       102",
"      </a>",
"      ]. Although the radiation group included mostly patients with these unfavorable features, the addition of consolidation RT resulted in superior progression-free survival (hazard ratio 0.40, 95 percent CI 0.23 to 0.69). Overall survival was also significantly better for those who received RT (HR, 0.47; 95% CI 0.29-0.77). Median follow-up was seven years.",
"     </li>",
"     <li>",
"      A single-center retrospective analysis of 104 patients with stage III HL who achieved a CR after ABVD and followed for a median of 5.8 years compared outcomes between the 40 patients who received consolidative RT and those who did not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/105\">",
"       105",
"      </a>",
"      ]. Patients who did not receive RT had inferior rates of disease-free survival at five (78 versus 94 percent) and 10 (45 versus 81 percent) years and lower rates of overall survival at five (91 versus 98 percent) and 10 (72 versus 80 percent) years post-treatment. The potential benefit from RT appeared to be greatest for patients with initial disease above the diaphragm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although not definitive, these observations provide support for combined modality treatment in this setting. Additional support for this approach comes from the extrapolation of data from patients with early stage disease with bulky mediastinal disease, which suggests that the addition of RT to chemotherapy results in significantly higher disease-free survival rates and a trend towards improved overall survival. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27496?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\", section on 'Combined modality therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the optimal use of adjuvant radiation remains ill-defined as part of initial therapy in patients with advanced stage HL, its use is further discussed below. The decision to incorporate adjuvant radiation into the treatment plan after ABVD must be individualized. Factors to be taken into account when making this decision include the patient&rsquo;s age, sex, history of prior radiation, and the size and location of the proposed radiation field. Given this information, we use the following approach to determining whether a patient should receive consolidation RT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with advanced stage HL and initial bulky mediastinal disease (&gt;10 cm or",
"      <span class=\"nowrap\">",
"       &gt;1/3",
"      </span>",
"      the chest diameter), we suggest the use of consolidation RT after ABVD rather than observation. The radiation dose is usually 20 to 36 Gy, and depends upon field size, initial disease volume, and response to chemotherapy. Observation may be appropriate for select patients, such as young women in whom substantial breast tissue would be included in the radiation fields.",
"     </li>",
"     <li>",
"      For patients with nonbulky advanced stage HL who achieve a CR with ABVD, we suggest observation rather than the use of consolidation RT.",
"     </li>",
"     <li>",
"      Patients treated with ABVD who achieve a PR, with residual PET abnormalities, should undergo biopsy of the suspected residual disease. If the biopsy demonstrates residual disease, additional therapy is administered as appropriate for",
"      <span class=\"nowrap\">",
"       relapsed/refractory",
"      </span>",
"      disease. Alternatively, consolidation with RT or close observation with short interval follow-up may be chosen in select circumstances in which a biopsy may prove difficult or dangerous, or when PET residual abnormality is of borderline significance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     With Stanford V",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) is a key component of the Stanford V protocol. This protocol delivers a brief intensive chemotherapy regimen (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ). RT, at a dose of 36 Gy, is initiated one to three weeks after the completion of chemotherapy and delivered to all sites of disease 5 cm or larger at diagnosis and to areas of macroscopic splenic involvement.",
"   </p>",
"   <p>",
"    The importance of initiating RT quickly after completing the chemotherapy segment of Stanford V was best illustrated in a randomized trial of Stanford V chemotherapy which did not administer RT according to the Stanford V design [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/80\">",
"     80",
"    </a>",
"    ]. This trial randomly assigned 355 patients with stage IIB-IV HL to receive ABVD, a modified Stanford V regimen, or MEC (a combination regimen using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    , CCNU,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31123?source=see_link\">",
"     vindesine",
"    </a>",
"    , alkeran,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , epidoxorubicin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ). RT was not mandatory and was administered to 66 and 62 percent of patients assigned to Stanford V and ABVD, respectively. At a median follow-up of 56 months, the five-year failure-free survival rates were 83 percent for ABVD, 85 percent for MEC, and 67 percent for Stanford V. In comparison, a randomized trial of ABVD versus Stanford V administered with RT according to the Stanford V design resulted in similar outcomes in the two arms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Stanford V'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all patients with advanced HL treated with Stanford V, we recommend consolidation RT to all sites of disease 5 cm or larger at diagnosis and to areas of macroscopic splenic involvement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     After BEACOPP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of radiation therapy (RT) improves freedom from treatment failure rates in patients with advanced stage HL who have residual disease after the completion of BEACOPP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/106\">",
"     106",
"    </a>",
"    ]. However, patients with advanced stage HL who still have residual disease on computed tomography scan after escalated BEACOPP but are PET-negative maintain a progression-free survival rate of 94 to 96 percent without receiving additional radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/63,107\">",
"     63,107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therefore, our current approach to the use of consolidation therapy for patient treated with BEACOPP is dependent upon their response to the initial chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who achieve a CR after BEACOPP, we suggest observation rather than RT.",
"     </li>",
"     <li>",
"      For patients who have residual disease on PET scan after BEACOPP, we suggest the use of consolidation RT rather than observation.",
"     </li>",
"     <li>",
"      RT consolidation should be considered for patients who have CT documented residual disease (&gt;2.5 cm) after BEACOPP but could not obtain post-treatment PET imaging.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Radiation toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The side effects of radiation therapy (RT) depend largely upon the area irradiated, the dose of radiation, and the technique employed. RT techniques have changed dramatically over the past few decades resulting in uncertainty regarding the long-term side effects of RT.",
"   </p>",
"   <p>",
"    In addition, there may be differences in both short-term and long-term toxicities when different combination chemotherapeutic regimens are combined with radiation therapy (RT). Although many of the short term toxicities can be avoided by administering sequential rather than concurrent chemotherapy and radiation, combinations of both treatments have the potential to increase late complications, most notably, secondary malignancies and cardiopulmonary toxicity. Approximately half of patients who received upper mediastinal or neck irradiation will develop hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=see_link&amp;anchor=H1167672644#H1167672644\">",
"     \"Long-term follow-up of the patient with classical Hodgkin lymphoma\", section on 'Follow-up for long-term complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Acute side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute side effects of RT include fatigue and a mild sun-exposure-like dermatitis in the involved field (",
"    <a class=\"graphic graphic_table graphicRef62894 \" href=\"mobipreview.htm?8/58/9132\">",
"     table 5",
"    </a>",
"    ). Irradiation of the head and neck can result in dry mouth, change in taste, and pharyngitis. Subdiaphragmatic irradiation is associated with a loss of appetite, nausea, and increased bowel movements. Myelosuppression can occur if more than one field is irradiated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/42/20137?source=see_link\">",
"     \"Gastrointestinal toxicity of radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complications occurring in fewer than 5 percent of patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mantle field irradiation can be associated with a spontaneously resolving electric shock-like sensation radiating down the backs of both legs with neck flexion (Lhermitte sign) typically presenting six weeks to three months after treatment.",
"     </li>",
"     <li>",
"      Mediastinal irradiation can be associated with radiation pneumonitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      acute pericarditis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=see_link\">",
"       \"Radiation-induced lung injury\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Cardiac and pulmonary toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mediastinal radiation therapy (RT) for HL may be a cause of late cardiac disease including constrictive or effusive pericarditis, conduction abnormalities, valvular defects, accelerated coronary artery atherosclerosis, or direct myocardial injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose of RT and field size are important risk factors for cardiac morbidity. Current practice, which restricts the dose to the whole heart, blocks the subcarinal region part way into treatment, limits concurrent exposure to cardiac toxins such as anthracyclines, and permits lower radiation dose and volume by the use of pre-irradiation chemotherapy, may be associated with a lower risk of cardiac toxicity.",
"   </p>",
"   <p>",
"    Pulmonary fibrosis can develop as a result of RT or chemotherapy for advanced HL. Decreased diffusing capacity (DLCO) and restrictive changes may be detected by pulmonary function testing prior to the onset of symptoms. Children may be more likely to show enhanced toxicity after combined modality treatment because of the increased sensitivity of the lung to damage from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/108\">",
"     108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=see_link\">",
"     \"Radiation-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    or thoracic irradiation increases the risk of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    lung toxicity, whether it is administered prior to or simultaneously with bleomycin. However, the rates of symptomatic pulmonary complications in patients treated with ABVD and radiation do not seem to be greater than after radiation alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/41,51\">",
"     41,51",
"    </a>",
"    ]. In one study of 60 patients with early-stage HL receiving ABVD with or without mediastinal irradiation, 53 percent reported dyspnea on exertion or cough during ABVD and 37 percent had a significant decline in forced vital capacity (FVC) and DLCO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/51\">",
"     51",
"    </a>",
"    ]. Following RT, there was a further decrease in FVC, but functional status was not significantly altered.",
"   </p>",
"   <p>",
"    Other chemotherapy regimens have also been associated with increased RT-associated pulmonary toxicity. In two studies in advanced-stage HL that used",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    together with other agents, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , severe pulmonary toxicity, including treatment-related fatalities, were recorded, leading to the termination of these treatment programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. Unacceptable rates of pulmonary toxicity have been observed in two of three studies of patients with early stage HL treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , bleomycin, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    plus radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/111-113\">",
"     111-113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Second malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) for HL has been associated with an increased risk of developing second malignancies. It is difficult to quantify the magnitude of this risk with modern RT because of the long latency for solid tumors, the potential contribution of chemotherapy, and the major recent changes in RT technique. The use of lower doses of RT and limited field size may reduce the risk of second cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/114,115\">",
"     114,115",
"    </a>",
"    ]. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     IS THERE A ROLE FOR TRANSPLANT?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation (HCT) is not recommended for patients with HL first remission. Instead, HCT is reserved for the treatment of relapsed disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/17/37145?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\", section on 'High dose chemotherapy and transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Attempts to identify a high risk population that might benefit from early HCT have been unsuccessful. Such a strategy would require the ability to clearly identify poor risk patients because of the 5 to 10 percent early mortality and the appreciable risk of late myelodysplastic syndrome or acute myeloid leukemia associated with HCT. Although a variety of prognostic factors can help to risk stratify patients with HL, it has proven difficult to identify a group of patients at very high risk for recurrence.",
"   </p>",
"   <p>",
"    An international trial randomly assigned 163 patients with poor risk disease who achieved CR or PR with four initial cycles of an ABVD containing regimen to high dose chemotherapy plus autologous HCT versus an additional four cycles of conventional chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/116\">",
"     116",
"    </a>",
"    ]. Poor risk disease was defined as the presence of at least two of the following features: high lactate dehydrogenase level, large mediastinal mass, involvement of more than one extranodal site, anemia, and inguinal involvement. After a median of 48 months, the five-year failure-free survival rate was 75 percent in the high-dose arm and 82 percent in the conventional arm and the five-year overall survival rate was 88 percent for both arms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     MODIFICATION FOR SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 3 percent of patients will be pregnant at the time HL is diagnosed. The management of such patients must take into account the effect of treatment on the fetus and the mother. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12793?source=see_link\">",
"     \"Management of classical Hodgkin lymphoma during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;HL has a bimodal age distribution curve. The pattern of age-specific incidence differs by geographic location and appears to parallel the level of industrial development. In the United States and other economically advantaged countries, there is one peak in young adults (approximately age 20 years) and one in older age (approximately age 65 years). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15578?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\", section on 'Incidence and age distribution'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The assessment of an older adult with HL includes those studies used for the pretreatment evaluation of younger adults with HL in addition to more specific investigations of physical functioning, nutrition, and comorbid conditions. The comprehensive geriatric assessment of cancer patients is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of older adults with HL has not been well studied. Older adults (ie, those greater than age 60) account for a minority of patients included in randomized trials and they are more likely to have comorbidities that can limit treatment options and increase the risk of toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. However, older adults should be offered curative therapy such as that used for younger adults whenever possible.",
"   </p>",
"   <p>",
"    For most older adults with HL, we suggest treatment with ABVD (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    ) rather than Stanford V or BEACOPP. This is primarily based upon the larger general experience with ABVD across all populations, increased toxicity with more intensive therapy, and lack of a survival benefit with Stanford V.",
"   </p>",
"   <p>",
"    Specifically, BEACOPP has been associated with unacceptable toxicities in patients over the age of 60. In one study, of 42 patients age 66 to 75 who received standard dose BEACOPP, 21 percent died of acute toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/71\">",
"     71",
"    </a>",
"    ]. When the Stanford V regimen is used in patients over age 50, the doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    are decreased (",
"    <a class=\"graphic graphic_table graphicRef74186 \" href=\"mobipreview.htm?7/60/8142\">",
"     table 3",
"    </a>",
"    ). The effect of these dose reductions on patient outcome is unknown.",
"   </p>",
"   <p>",
"    The relatively poor results for elderly patients are accompanied by difficulties in maintaining dose intensity with standard HL regimens. In an attempt to improve outcomes, prospective trials have evaluated the use of other regimens in this population. However, none of these has demonstrated superior outcomes in a randomized trial. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In one small study employing CHOP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) for elderly HL patients, dose intensity was maintained with this every three week regimen and good results were achieved [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/119\">",
"       119",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In another study of 59 older adults treated with the novel combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      (PVAG), toxicity was acceptable and rates of complete response, progression-free survival at three years, and overall survival at three years were 78, 66 and 58 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/120\">",
"       120",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In another study, 72 patients with advanced stage HL were treated with VEPEMB (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ) with rates of complete remission and overall and progression-free survival at three years of 61, 58, and 66 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/121\">",
"       121",
"      </a>",
"      ]. All patients required granulocyte colony stimulating factor support and there were three septic deaths. It is not clear whether this regimen is more effective or better tolerated than ABVD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;It appears that adult treatment protocols may be safe and provide comparable efficacy to pediatric protocols in the treatment of adolescents with HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/54/39786/abstract/122\">",
"     122",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/6/32874?source=see_link\">",
"     \"Overview of Hodgkin lymphoma in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98393357\">",
"    <span class=\"h2\">",
"     HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with HIV who develop HL is complicated by their immunocompromised state and also requires specific treatment for their HIV. As such, treatment of these patients is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38346?source=see_link\">",
"     \"AIDS-related lymphomas: Treatment of systemic lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/31/30202?source=see_link&amp;anchor=H1560506291#H1560506291\">",
"     \"HIV infection and malignancy: Management considerations\", section on 'Hodgkin lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     MONITORING DURING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HL are re-evaluated at regular intervals during treatment to assess the response. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30007?source=see_link\">",
"     \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the completion of therapy, patients are assessed for disease response using the International Working Group response criteria that incorporates findings on computed tomography and positron emission tomography scans. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30007?source=see_link&amp;anchor=H1515431811#H1515431811\">",
"     \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\", section on 'Response categories'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients treated for HL must also be followed at regular intervals to assess for recurrent disease and long-term complications of therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=see_link&amp;anchor=H1167672602#H1167672602\">",
"     \"Long-term follow-up of the patient with classical Hodgkin lymphoma\", section on 'Follow-up for relapse'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=see_link&amp;anchor=H1167672644#H1167672644\">",
"     \"Long-term follow-up of the patient with classical Hodgkin lymphoma\", section on 'Follow-up for long-term complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/37/13908?source=see_link\">",
"       \"Patient information: Hodgkin lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of Hodgkin lymphoma (HL, formerly called Hodgkin's disease) has been established, subsequent therapy is based upon the stage of the disease, as currently defined by the Cotswolds classification (",
"    <a class=\"graphic graphic_table graphicRef66651 \" href=\"mobipreview.htm?19/23/19836\">",
"     table 1",
"    </a>",
"    ). In this discussion, advanced stage HL refers to clinical stage (CS) III and IV disease. CS III describes involvement of lymph nodes or lymphoid structures on both sides of the diaphragm. CS IV refers to diffuse or disseminated involvement of one or more extranodal organs or tissues, with or without lymph node disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most widely used regimen for advanced stage HL is ABVD (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ). Other regimens such as BEACOPP (bleomycin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , doxorubicin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) and Stanford V (doxorubicin, vinblastine,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"       mechlorethamine",
"      </a>",
"      , vincristine, bleomycin, etoposide, and prednisone) are used in selected cases (",
"      <a class=\"graphic graphic_table graphicRef74186 \" href=\"mobipreview.htm?7/60/8142\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite the increasing availability of guidelines for the treatment of Hodgkin lymphoma, there must remain room for individualization of treatment. In particular, patient preference must be considered with different treatment options, some of which result in a higher recurrence risk at the gain of less toxic initial treatment. Treatment should also be individualized when a particular approach might result in a higher risk of acute",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      late complications. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with advanced stage HL, we suggest ABVD treatment (",
"      <a class=\"graphic graphic_table graphicRef68131 \" href=\"mobipreview.htm?0/59/958\">",
"       table 4",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Alternative options include escalated BEACOPP and Stanford V. Escalated BEACOPP programs have shown advantages in freedom from progression when compared with ABVD and overall survival when compared with",
"      <span class=\"nowrap\">",
"       COPP/ABVD.",
"      </span>",
"      These advantages are most marked among higher risk IPS patients and this more intense regimen is a reasonable alternative to ABVD for these patients with the highest risk of relapse (",
"      <a class=\"graphic graphic_table graphicRef76219 \" href=\"mobipreview.htm?11/50/12077\">",
"       table 2",
"      </a>",
"      ). Toxicities associated with the administration of escalated BEACOPP in the elderly make it inappropriate for this population. Stanford V may be chosen for some patients without high risk features because of its short administration schedule (12 versus 24 to 32 weeks) and decreased pulmonary toxicity and may have advantages for certain patients, particularly those for whom radiation will be part of their planned therapy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'ABVD chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'BEACOPP chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Stanford V'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of consolidation radiotherapy (RT) after chemotherapy induction for advanced stage HL is controversial. RT appears to improve freedom from progression but not overall survival. Its use depends primarily upon the initial chemotherapy administered and the patient's response to that chemotherapy. RT is a key component of the Stanford V protocol. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'General'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'With Stanford V'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision to proceed with adjuvant radiation after ABVD must be individualized. Factors to be taken into account when making this decision include the patient&rsquo;s age, sex, history of prior radiation, and the size and location of the proposed radiation field. In general, we use the following approach:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with advanced stage HL and initial bulky mediastinal disease (&gt;10 cm or",
"      <span class=\"nowrap\">",
"       &gt;1/3",
"      </span>",
"      the chest diameter), we suggest the use of consolidation RT after ABVD rather than observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The radiation dose is usually 20 to 36 Gy, and depends upon field size, initial disease volume, and response to chemotherapy. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'After ABVD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with nonbulky advanced stage HL who achieve a complete remission with ABVD, we suggest observation rather than the use of consolidation RT (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients treated with ABVD who achieve a PR, with residual PET abnormalities, should undergo biopsy of the suspected residual disease. If the biopsy demonstrates residual disease, additional therapy is administered as appropriate for",
"      <span class=\"nowrap\">",
"       relapsed/refractory",
"      </span>",
"      disease. Alternatively, consolidation with RT or close observation with short interval follow-up may be chosen in select circumstances in which a biopsy may prove difficult or dangerous or when PET residual abnormality is of borderline significance.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/1\">",
"      Mauch PM, Kalish LA, Kadin M, et al. Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer 1993; 71:2062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/2\">",
"      Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003; 21:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/3\">",
"      Johnson PW, Radford JA, Cullen MH, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 2005; 23:9208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/4\">",
"      Carde P. The chemotherapy/radiation balance in advanced Hodgkin's lymphoma: overweight which side? J Clin Oncol 2005; 23:9058.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/6\">",
"      Tesch H, Diehl V, Lathan B, et al. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. Blood 1998; 92:4560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/7\">",
"      Viviani S, Bonfante V, Santoro A, et al. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. Cancer J Sci Am 1999; 5:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/8\">",
"      Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/9\">",
"      Djeridane M, Oudard S, Escoffre-Barbe M, et al. Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leuc&eacute;mies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial. Cancer 2002; 95:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/10\">",
"      Longo DL, Duffey PL, DeVita VT Jr, et al. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. J Clin Oncol 1991; 9:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/11\">",
"      Vinciguerra V, Propert KJ, Coleman M, et al. Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospectively randomized study by the Cancer and Leukemia Group B. J Clin Oncol 1986; 4:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/12\">",
"      DeVita VT Jr, Simon RM, Hubbard SM, et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980; 92:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/13\">",
"      Horning SJ, Hoppe RT, Kaplan HS, Rosenberg SA. Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med 1981; 304:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/14\">",
"      Chapman RM, Sutcliffe SB, Malpas JS. Male gonadal dysfunction in Hodgkin's disease. A prospective study. JAMA 1981; 245:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/15\">",
"      Coleman CN, Williams CJ, Flint A, et al. Hematologic neoplasia in patients treated for Hodgkin's disease. N Engl J Med 1977; 297:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/16\">",
"      Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/17\">",
"      Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med 1986; 104:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/18\">",
"      Bakemeier RF, Anderson JR, Costello W, et al. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. Ann Intern Med 1984; 101:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/19\">",
"      Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/20\">",
"      Somers R, Carde P, Henry-Amar M, et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 1994; 12:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/21\">",
"      Connors JM, Klimo P, Adams G, et al. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 1997; 15:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/22\">",
"      Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 1996; 14:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/23\">",
"      Glick JH, Young ML, Harrington D, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 1998; 16:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/24\">",
"      Cantin G, L'Esp&eacute;rance B, Yelle L, et al. Two different schedules for integrating filgrastim as adjuvant therapy in the treatment of patients with advanced stage Hodgkin's lymphoma receiving MOPP/ABV hybrid chemotherapy. Cancer Chemother Pharmacol 1999; 43:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/25\">",
"      Richards MA, Waxman JH, Man T, et al. EVA treatment for recurrent or unresponsive Hodgkin's disease. Cancer Chemother Pharmacol 1986; 18:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/26\">",
"      Canellos GP, Gollub J, Neuberg D, et al. Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Ann Oncol 2003; 14:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/27\">",
"      Kavan P, Kabickova E, Koutecky J, et al. Treatment of Hodgkin's disease in children with VAMP (vinblastine, adriamycin, methotrexate, prednisone) and VEPA (vinblastine, etoposide, prednisone, adriamycin). Pediatr Hematol Oncol 1999; 16:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/28\">",
"      Nissen NI, Pajak TF, Glidewell O, et al. A comparative study of a BCNU containing 4-drug program versus MOPP versus 3-drug combinations in advanced Hodgkin's disease: a cooperative study by the Cancer and Leukemia Group B. Cancer 1979; 43:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/29\">",
"      McElwain TJ, Toy J, Smith E, et al. A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease. Br J Cancer 1977; 36:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/30\">",
"      Sutcliffe SB, Wrigley PF, Peto J, et al. MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J 1978; 1:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/31\">",
"      Hancock BW. Randomised study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease. British National Lymphoma Investigation. Radiother Oncol 1986; 7:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/32\">",
"      Bloomfield CD, Weiss RB, Fortuny I, et al. Combinaed chemotherapy with cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for patients with advanced Hodgkin's disease. An alternative program to MOPP. Cancer 1976; 38:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/33\">",
"      Cooper MR, Pajak TF, Nissen NI, et al. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer 1980; 46:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/34\">",
"      Selby P, Patel P, Milan S, et al. ChlVPP combination chemotherapy for Hodgkin's disease: long-term results. Br J Cancer 1990; 62:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/35\">",
"      Vose J, Armitage J, Weisenburger D, et al. ChlVPP--an effective and well-tolerated alternative to MOPP therapy for Hodgkin's disease. Am J Clin Oncol 1988; 11:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/36\">",
"      Weekes CD, Vose JM, Lynch JC, et al. Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol 2002; 20:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/37\">",
"      ChlVPP therapy for Hodgkin's disease: experience of 960 patients. The International ChlVPP Treatment Group. Ann Oncol 1995; 6:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/38\">",
"      Simmonds PD, Mead GM, Sweetenham JW, et al. PACE BOM chemotherapy: a 12-week regimen for advanced Hodgkin's disease. Ann Oncol 1997; 8:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/39\">",
"      Radford JA, Rohatiner AZ, Ryder WD, et al. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol 2002; 20:2988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/40\">",
"      Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/41\">",
"      Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/42\">",
"      Bonfante V, Santoro A, Viviani S, et al. ABVD in the treatment of Hodgkin's disease. Semin Oncol 1992; 19:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/43\">",
"      Johnson P, Hoskin P, Horwich A, et al. Stanford V (SV) regimen versus ABVD for the treatment of advanced Hodgkin lymphoma (HL): Results of a UK NCRI/LTO randomised phase II trial (abstract). Blood 2004; 104:93a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/44\">",
"      Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 2009; 27:5390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/45\">",
"      Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009; 27:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/46\">",
"      Boleti E, Mead GM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol 2007; 18:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/47\">",
"      Evens AM, Cilley J, Ortiz T, et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007; 137:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/48\">",
"      Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005; 23:7614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/49\">",
"      Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993; 11:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/50\">",
"      Horning SJ, Adhikari A, Rizk N, et al. Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study. J Clin Oncol 1994; 12:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/51\">",
"      Hirsch A, Vander Els N, Straus DJ, et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 1996; 14:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/52\">",
"      Mefferd JM, Donaldson SS, Link MP. Pediatric Hodgkin's disease: pulmonary, cardiac, and thyroid function following combined modality therapy. Int J Radiat Oncol Biol Phys 1989; 16:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/53\">",
"      Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/54\">",
"      Brice P, Tredaniel J, Monsuez JJ, et al. Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favorable Hodgkin's disease. Ann Oncol 1991; 2 Suppl 2:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/55\">",
"      Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007; 99:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/56\">",
"      Viviani S, Santoro A, Ragni G, et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985; 21:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/57\">",
"      Anselmo AP, Cartoni C, Bellantuono P, et al. Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP. Haematologica 1990; 75:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/58\">",
"      Hasenclever D, Loeffler M, Diehl V. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 1996; 7 Suppl 4:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/59\">",
"      Diehl V, Sieber M, R&uuml;ffer U, et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol 1997; 8:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/60\">",
"      Loeffler M, Hasenclever D, Diehl V. Model based development of the BEACOPP regimen for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 1998; 9 Suppl 5:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/61\">",
"      Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011; 365:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/62\">",
"      Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/63\">",
"      Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012; 379:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/64\">",
"      Diehl V, Franklin J, Hasenclever D, et al. BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 1998; 9 Suppl 5:S67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/65\">",
"      Sieber M, Bredenfeld H, Josting A, et al. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/66\">",
"      Diehl V, Franklin J, Hasenclever D, et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998; 16:3810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/67\">",
"      Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009; 27:4548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/68\">",
"      Bauer K, Skoetz N, Monsef I, et al. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 2011; :CD007941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/69\">",
"      Engel C, Loeffler M, Schmitz S, et al. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). Ann Oncol 2000; 11:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/70\">",
"      Engert A, Josting A, Haverkamp H, et al. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol 2010; 28:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/71\">",
"      Ballova V, R&uuml;ffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005; 16:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/72\">",
"      Scholz M, Engert A, Franklin J, et al. Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. Ann Oncol 2011; 22:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/73\">",
"      Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005; 23:7555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/74\">",
"      Behringer K, Wildt L, Mueller H, et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol 2010; 21:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/75\">",
"      Behringer K, Mueller H, Goergen H, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 2013; 31:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/76\">",
"      Sieniawski M, Reineke T, Nogova L, et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008; 111:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/77\">",
"      Bartlett NL, Rosenberg SA, Hoppe RT, et al. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995; 13:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/78\">",
"      Horning SJ, Hoppe RT, Advani R, et al. Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: Mature data in early and advanced stage patients (abstract). Blood 2004; 104:92a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/79\">",
"      Horning SJ, Williams J, Bartlett NL, et al. Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol 2000; 18:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/80\">",
"      Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005; 23:9198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/81\">",
"      Gordon LI, Hong F, Fisher RI, et al. A randomized phase III trial of ABVD vs Stanford V +/- radiation therapy in locally extensive and advanced stage Hodgkin's lymphoma: An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496); abstract 415. Blood 2010; 116:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/82\">",
"      Abuzetun JY, Loberiza F, Vose J, et al. The Stanford V regimen is effective in patients with good risk Hodgkin lymphoma but radiotherapy is a necessary component. Br J Haematol 2009; 144:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/83\">",
"      Edwards-Bennett SM, Jacks LM, Moskowitz CH, et al. Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Ann Oncol 2010; 21:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/84\">",
"      Chisesi T, Bellei M, Luminari S, et al. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. J Clin Oncol 2011; 29:4227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/85\">",
"      Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 2013; 31:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/86\">",
"      Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/87\">",
"      Gordon LI, Longnecker R. Off-targeting oft-targeted CD20 in cHL. Blood 2012; 119:4095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/88\">",
"      Younes A, Oki Y, McLaughlin P, et al. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 2012; 119:4123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/89\">",
"      Kasamon YL, Jacene HA, Gocke CD, et al. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood 2012; 119:4129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/90\">",
"      Hoppe RT. Hodgkin's disease--the role of radiation therapy in advanced disease. Ann Oncol 1996; 7 Suppl 4:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/91\">",
"      Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 1998; 16:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/92\">",
"      Yahalom J, Ryu J, Straus DJ, et al. Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations. J Clin Oncol 1991; 9:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/93\">",
"      Fabian CJ, Mansfield CM, Dahlberg S, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med 1994; 120:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/94\">",
"      Brizel DM, Winer EP, Prosnitz LR, et al. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. Int J Radiat Oncol Biol Phys 1990; 19:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/95\">",
"      Diehl V, Loeffler M, Pfreundschuh M, et al. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG). Ann Oncol 1995; 6:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/96\">",
"      Ferm&eacute; C, Sebban C, Hennequin C, et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'&eacute;tudes des lymphomes de l'Adulte H89 trial. Blood 2000; 95:2246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/97\">",
"      Brice P, Colin P, Berger F, et al. Advanced Hodgkin disease with large mediastinal involvement can be treated with eight cycles of chemotherapy alone after a major response to six cycles of chemotherapy: a study of 82 patients from the Groupes d'Etudes des Lymphomes de l'Adulte H89 trial. Cancer 2001; 92:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/98\">",
"      Ferm&eacute; C, Mounier N, Casasnovas O, et al. Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 107:4636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/99\">",
"      Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/100\">",
"      Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004; 22:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/101\">",
"      Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20:3765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/102\">",
"      Johnson PW, Sydes MR, Hancock BW, et al. Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol 2010; 28:3352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/103\">",
"      Aleman BM, Raemaekers JM, Tomii R, et al. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2007; 67:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/104\">",
"      Lee SM, Radford JA, Ryder WD, et al. Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy. Br J Cancer 1997; 75:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/105\">",
"      Phan J, Mazloom A, Abboud M, et al. Consolidative radiation therapy for stage III Hodgkin lymphoma in patients who achieve complete response after ABVD chemotherapy. Am J Clin Oncol 2011; 34:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/106\">",
"      Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011; 29:4234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/107\">",
"      Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008; 112:3989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/108\">",
"      Lazo JS, Sebti SM, Schellens JH. Bleomycin. Cancer Chemother Biol Response Modif 1996; 16:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/109\">",
"      Bredenfeld H, Franklin J, Nogova L, et al. Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2004; 22:2424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/110\">",
"      Friedberg JW, Neuberg D, Kim H, et al. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. Cancer 2003; 98:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/111\">",
"      Horning SJ, Hoppe RT, Mason J, et al. Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 1997; 15:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/112\">",
"      Gobbi PG, Pieresca C, Frassoldati A, et al. Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi Experience. J Clin Oncol 1996; 14:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/113\">",
"      Bates NP, Williams MV, Bessell EM, et al. Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: a British National Lymphoma Investigation pilot study. J Clin Oncol 1994; 12:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/114\">",
"      De Bruin ML, Sparidans J, van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009; 27:4239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/115\">",
"      Hodgson DC, Koh ES, Tran TH, et al. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 2007; 110:2576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/116\">",
"      Federico M, Bellei M, Brice P, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 2003; 21:2320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/117\">",
"      Proctor SJ, Wilkinson J, Sieniawski M. Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future. Crit Rev Oncol Hematol 2009; 71:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/118\">",
"      Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 2012; 119:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/119\">",
"      Kolstad A, Nome O, Delabie J, et al. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leuk Lymphoma 2007; 48:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/120\">",
"      B&ouml;ll B, Bredenfeld H, G&ouml;rgen H, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood 2011; 118:6292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/121\">",
"      Proctor SJ, Wilkinson J, Jones G, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood 2012; 119:6005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/54/39786/abstract/122\">",
"      Eichenauer DA, Bredenfeld H, Haverkamp H, et al. Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group. J Clin Oncol 2009; 27:6079.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4689 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-59E8FFCE15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_54_39786=[""].join("\n");
var outline_f38_54_39786=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      International prognostic score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ABVD chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - ABVD efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - ABVD toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5413363\">",
"      Acute",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5413388\">",
"      Long-term",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      BEACOPP chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - BEACOPP efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - BEACOPP toxicities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5413529\">",
"      Short term",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5413542\">",
"      Long term",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Stanford V",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13244407\">",
"      Is there a role for rituximab?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      IS THERE A ROLE FOR RADIATION?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Radiation efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - General",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - After ABVD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - With Stanford V",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - After BEACOPP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Radiation toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Acute side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Cardiac and pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Second malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      IS THERE A ROLE FOR TRANSPLANT?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      MODIFICATION FOR SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98393357\">",
"      HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      MONITORING DURING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4689\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4689|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/23/19836\" title=\"table 1\">",
"      Cotswolds system in HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/50/12077\" title=\"table 2\">",
"      IPS Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/60/8142\" title=\"table 3\">",
"      Comb chemo reg HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/59/958\" title=\"table 4\">",
"      ABVD chemotherapy for Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/58/9132\" title=\"table 5\">",
"      Comb modal tox HL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?4/32/4609?source=related_link\" title=\"calculator 1\">",
"      Calculator: International Prognostic Score in Hodgkin Lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38346?source=related_link\">",
"      AIDS-related lymphomas: Treatment of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15578?source=related_link\">",
"      Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/42/20137?source=related_link\">",
"      Gastrointestinal toxicity of radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29206?source=related_link\">",
"      Initial evaluation and diagnosis of Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=related_link\">",
"      Long-term follow-up of the patient with classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12793?source=related_link\">",
"      Management of classical Hodgkin lymphoma during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30007?source=related_link\">",
"      Monitoring of the patient with classical Hodgkin lymphoma during and after treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/6/32874?source=related_link\">",
"      Overview of Hodgkin lymphoma in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13512?source=related_link\">",
"      Overview of the treatment of classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/37/13908?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7784?source=related_link\">",
"      Relapse of classical Hodgkin lymphoma after initial radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=related_link\">",
"      Second malignancies after treatment of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/37/14935?source=related_link\">",
"      Staging and prognosis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11770?source=related_link\">",
"      Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/45/34520?source=related_link\">",
"      Treatment of nodular lymphocyte-predominant Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/17/37145?source=related_link\">",
"      Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27496?source=related_link\">",
"      Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_54_39787="DSM-IV-TR criteria for specific phobia";
var content_f38_54_39787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F81555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F81555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR criteria for specific phobia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Marked and persistent fear that is excessive or unreasonable, cued by the presence or anticipation of a specific object or situation (eg, flying, heights, animals, receiving an injection, seeing blood).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exposure to the phobic stimulus almost invariably provokes an immediate anxiety response, which may take the form of a situationally bound or situationally predisposed panic attack. (Note: In children, the anxiety may be expressed by crying, tantrums, freezing, or clinging.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The person recognizes that the fear is excessive or unreasonable. (Note: In children, this feature may be absent.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The phobic situation(s) is avoided or else endured with intense anxiety or distress.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational (or academic) functioning, or social activities or relationships, or there is marked distress about having the phobia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In individuals under age 18 years, the duration is at least 6 months.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The anxiety, panic attacks, or phobic avoidance associated with the specific object or situation are not better accounted for by another mental disorder, such as obsessive compulsive disorder (eg, fear of dirt in someone with an obsession about contamination), separation anxiety disorder (eg, avoidance of school), social phobia (eg, avoidance of social situations because of fear of embarrassment), panic disorder with agoraphobia, or agoraphobia without history of panic disorder.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, (Copyright 2000). American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_54_39787=[""].join("\n");
var outline_f38_54_39787=null;
var title_f38_54_39788="Classification of gastritis and gastropathy";
var content_f38_54_39788=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of gastritis and gastropathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Acute forms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute hemorrhagic and erosive gastropathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute Helicobacter pylori gastritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Uncommon acute infectious gastritides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Common forms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Helicobacter pylori gastritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Chemical gastropathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Aspirin and other nonsteroidal antiinflammatory drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Bile reflux",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Alcohol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Others (?)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Metaplastic atrophic gastritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Autoimmune",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Environmental",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic gastritis/gastropathy of indeterminate type",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Uncommon forms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Postantrectomy atrophic gastritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Eosinophilic gastritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Infectious gastritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Bacterial, other than Helicobacter pylori",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Helicobacter heilmannii",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Phlegmonous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Mycobacterial",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Syphilitic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Viral",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Parasitic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Fungal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Crohn's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Isolated granulomatous gastritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lymphocytic gastritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            M&eacute;n&eacute;trier's disease",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_54_39788=[""].join("\n");
var outline_f38_54_39788=null;
var title_f38_54_39789="Contents: Sleep";
var content_f38_54_39789=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?18/22/18798\">",
"       Patient Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Sleep",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Sleep",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Daytime sleepiness",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/4/38978\">",
"           Patient information: Daytime sleepiness (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Insomnia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/16/2306\">",
"           Patient information: Insomnia (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/58/22434\">",
"           Patient information: Insomnia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/24/28035\">",
"           Patient information: Insomnia treatments (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/25/16786\">",
"           Patient information: Sleep apnea (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Jet lag",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/9/19602\">",
"           Patient information: Jet lag (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Narcolepsy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/19/27953\">",
"           Patient information: Narcolepsy (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Restless legs syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/29/20946\">",
"           Patient information: Restless legs syndrome (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sleep apnea",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/58/22434\">",
"           Patient information: Insomnia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/25/16786\">",
"           Patient information: Sleep apnea (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/25/26003\">",
"           Patient information: Sleep apnea in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tests",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/5/35921\">",
"           Patient information: What is a sleep study? (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-3E686D66DC-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f38_54_39789=[""].join("\n");
var outline_f38_54_39789=null;
var title_f38_54_39790="ECG blocked APB";
var content_f38_54_39790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram (ECG) strips showing a blocked atrial premature beat (APB)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 199px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Simultaneous electrocardiographic leads V1, II, and V5 show an atrial premature beat (red arrow) that is blocked within the atrioventricular node and not conducted to the ventricle. The P wave of the atrial premature beats alters the terminal portion of preceding T wave, seen in leads V1 and II, but not in lead V5.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_54_39790=[""].join("\n");
var outline_f38_54_39790=null;
var title_f38_54_39791="Angioedema and hives face";
var content_f38_54_39791=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F66159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F66159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Angioedema and hives face",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 200px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Facial angioedema and urticaria (forehead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_54_39791=[""].join("\n");
var outline_f38_54_39791=null;
